A comprehensive review of SHP2 and its role in cancer

Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein tyrosine phosphatase ubiquitously expressed mainly in the cytoplasm of several tissues. SHP2 modulates diverse cell signaling events that control metabolism, cell growth, differentiation, cell migration, transc...

Full description

Saved in:
Bibliographic Details
Published inCellular oncology (Dordrecht) Vol. 45; no. 5; pp. 729 - 753
Main Authors Asmamaw, Moges Dessale, Shi, Xiao-Jing, Zhang, Li-Rong, Liu, Hong-Min
Format Journal Article
LanguageEnglish
Published Dordrecht Springer Netherlands 01.10.2022
Springer Nature B.V
Subjects
1-Phosphatidylinositol 3-kinase
AKT protein
Allosteric properties
Antineoplastic drugs
Antitumor agents
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Cell differentiation
Cell migration
Cell signaling
Cytokines
Cytoplasm
Developmental disabilities
Extracellular signal-regulated kinase
Growth factors
Homology
Kinases
miRNA
Oncology
Pathology
PD-1 protein
Phosphatase
Protein-tyrosine-phosphatase
Solid tumors
SUMO protein
Therapeutic targets
Tumor suppressor genes
Ubiquitination
Gab1
SHP2
PTPN11
Tyrosine phosphorylation
SHP2 inhibitors
Online AccessGet full text
ISSN2211-3428
2211-3436
2211-3436
DOI10.1007/s13402-022-00698-1

Cover

Abstract Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein tyrosine phosphatase ubiquitously expressed mainly in the cytoplasm of several tissues. SHP2 modulates diverse cell signaling events that control metabolism, cell growth, differentiation, cell migration, transcription and oncogenic transformation. It interacts with diverse molecules in the cell, and regulates key signaling events including RAS/ERK, PI3K/AKT, JAK/STAT and PD-1 pathways downstream of several receptor tyrosine kinases (RTKs) upon stimulation by growth factors and cytokines. SHP2 acts as both a phosphatase and a scaffold, and plays prominently oncogenic functions but can be tumor suppressor in a context-dependent manner. It typically acts as a positive regulator of RTKs signaling with some inhibitory functions reported as well. SHP2 expression and activity is regulated by such factors as allosteric autoinhibition, microRNAs, ubiquitination and SUMOylation. Dysregulation of SHP2 expression or activity causes many developmental diseases, and hematological and solid tumors. Moreover, upregulated SHP2 expression or activity also decreases sensitivity of cancer cells to anticancer drugs. SHP2 is now considered as a compelling anticancer drug target and several classes of SHP2 inhibitors with different mode of action are developed with some already in clinical trial phases. Moreover, novel SHP2 substrates and functions are rapidly growing both in cell and cancer. In view of this, we comprehensively and thoroughly reviewed literatures about SHP2 regulatory mechanisms, substrates and binding partners, biological functions, roles in human cancers, and different classes of small molecule inhibitors target this oncoprotein in cancer.
AbstractList Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein tyrosine phosphatase ubiquitously expressed mainly in the cytoplasm of several tissues. SHP2 modulates diverse cell signaling events that control metabolism, cell growth, differentiation, cell migration, transcription and oncogenic transformation. It interacts with diverse molecules in the cell, and regulates key signaling events including RAS/ERK, PI3K/AKT, JAK/STAT and PD-1 pathways downstream of several receptor tyrosine kinases (RTKs) upon stimulation by growth factors and cytokines. SHP2 acts as both a phosphatase and a scaffold, and plays prominently oncogenic functions but can be tumor suppressor in a context-dependent manner. It typically acts as a positive regulator of RTKs signaling with some inhibitory functions reported as well. SHP2 expression and activity is regulated by such factors as allosteric autoinhibition, microRNAs, ubiquitination and SUMOylation. Dysregulation of SHP2 expression or activity causes many developmental diseases, and hematological and solid tumors. Moreover, upregulated SHP2 expression or activity also decreases sensitivity of cancer cells to anticancer drugs. SHP2 is now considered as a compelling anticancer drug target and several classes of SHP2 inhibitors with different mode of action are developed with some already in clinical trial phases. Moreover, novel SHP2 substrates and functions are rapidly growing both in cell and cancer. In view of this, we comprehensively and thoroughly reviewed literatures about SHP2 regulatory mechanisms, substrates and binding partners, biological functions, roles in human cancers, and different classes of small molecule inhibitors target this oncoprotein in cancer.
Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein tyrosine phosphatase ubiquitously expressed mainly in the cytoplasm of several tissues. SHP2 modulates diverse cell signaling events that control metabolism, cell growth, differentiation, cell migration, transcription and oncogenic transformation. It interacts with diverse molecules in the cell, and regulates key signaling events including RAS/ERK, PI3K/AKT, JAK/STAT and PD-1 pathways downstream of several receptor tyrosine kinases (RTKs) upon stimulation by growth factors and cytokines. SHP2 acts as both a phosphatase and a scaffold, and plays prominently oncogenic functions but can be tumor suppressor in a context-dependent manner. It typically acts as a positive regulator of RTKs signaling with some inhibitory functions reported as well. SHP2 expression and activity is regulated by such factors as allosteric autoinhibition, microRNAs, ubiquitination and SUMOylation. Dysregulation of SHP2 expression or activity causes many developmental diseases, and hematological and solid tumors. Moreover, upregulated SHP2 expression or activity also decreases sensitivity of cancer cells to anticancer drugs. SHP2 is now considered as a compelling anticancer drug target and several classes of SHP2 inhibitors with different mode of action are developed with some already in clinical trial phases. Moreover, novel SHP2 substrates and functions are rapidly growing both in cell and cancer. In view of this, we comprehensively and thoroughly reviewed literatures about SHP2 regulatory mechanisms, substrates and binding partners, biological functions, roles in human cancers, and different classes of small molecule inhibitors target this oncoprotein in cancer.Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein tyrosine phosphatase ubiquitously expressed mainly in the cytoplasm of several tissues. SHP2 modulates diverse cell signaling events that control metabolism, cell growth, differentiation, cell migration, transcription and oncogenic transformation. It interacts with diverse molecules in the cell, and regulates key signaling events including RAS/ERK, PI3K/AKT, JAK/STAT and PD-1 pathways downstream of several receptor tyrosine kinases (RTKs) upon stimulation by growth factors and cytokines. SHP2 acts as both a phosphatase and a scaffold, and plays prominently oncogenic functions but can be tumor suppressor in a context-dependent manner. It typically acts as a positive regulator of RTKs signaling with some inhibitory functions reported as well. SHP2 expression and activity is regulated by such factors as allosteric autoinhibition, microRNAs, ubiquitination and SUMOylation. Dysregulation of SHP2 expression or activity causes many developmental diseases, and hematological and solid tumors. Moreover, upregulated SHP2 expression or activity also decreases sensitivity of cancer cells to anticancer drugs. SHP2 is now considered as a compelling anticancer drug target and several classes of SHP2 inhibitors with different mode of action are developed with some already in clinical trial phases. Moreover, novel SHP2 substrates and functions are rapidly growing both in cell and cancer. In view of this, we comprehensively and thoroughly reviewed literatures about SHP2 regulatory mechanisms, substrates and binding partners, biological functions, roles in human cancers, and different classes of small molecule inhibitors target this oncoprotein in cancer.
Abstract Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein tyrosine phosphatase ubiquitously expressed mainly in the cytoplasm of several tissues. SHP2 modulates diverse cell signaling events that control metabolism, cell growth, differentiation, cell migration, transcription and oncogenic transformation. It interacts with diverse molecules in the cell, and regulates key signaling events including RAS/ERK, PI3K/AKT, JAK/STAT and PD-1 pathways downstream of several receptor tyrosine kinases (RTKs) upon stimulation by growth factors and cytokines. SHP2 acts as both a phosphatase and a scaffold, and plays prominently oncogenic functions but can be tumor suppressor in a context-dependent manner. It typically acts as a positive regulator of RTKs signaling with some inhibitory functions reported as well. SHP2 expression and activity is regulated by such factors as allosteric autoinhibition, microRNAs, ubiquitination and SUMOylation. Dysregulation of SHP2 expression or activity causes many developmental diseases, and hematological and solid tumors. Moreover, upregulated SHP2 expression or activity also decreases sensitivity of cancer cells to anticancer drugs. SHP2 is now considered as a compelling anticancer drug target and several classes of SHP2 inhibitors with different mode of action are developed with some already in clinical trial phases. Moreover, novel SHP2 substrates and functions are rapidly growing both in cell and cancer. In view of this, we comprehensively and thoroughly reviewed literatures about SHP2 regulatory mechanisms, substrates and binding partners, biological functions, roles in human cancers, and different classes of small molecule inhibitors target this oncoprotein in cancer.
Author Zhang, Li-Rong
Shi, Xiao-Jing
Liu, Hong-Min
Asmamaw, Moges Dessale
Author_xml – sequence: 1
  givenname: Moges Dessale
  orcidid: 0000-0002-8746-9666
  surname: Asmamaw
  fullname: Asmamaw, Moges Dessale
  organization: Department of Pharmacology, School of Basic Medical Sciences, State Key Laboratory for Esophageal Cancer Prevention and Treatment, Zhengzhou University
– sequence: 2
  givenname: Xiao-Jing
  surname: Shi
  fullname: Shi, Xiao-Jing
  organization: Academy of Medical Sciences, Zhengzhou University
– sequence: 3
  givenname: Li-Rong
  surname: Zhang
  fullname: Zhang, Li-Rong
  email: zhanglirongzzu@126.com
  organization: Department of Pharmacology, School of Basic Medical Sciences, State Key Laboratory for Esophageal Cancer Prevention and Treatment, Zhengzhou University
– sequence: 4
  givenname: Hong-Min
  orcidid: 0000-0001-6771-9421
  surname: Liu
  fullname: Liu, Hong-Min
  email: liuhm@zzu.edu.cn
  organization: School of Pharmaceutical Sciences, Zhengzhou University, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China
BookMark eNp9kM1KAzEURoNUsNa-gKuAGzej-ZvMzLIUtUJBQV2HmN5oyjSpybTi25s6otBFA5fkwjnh4ztFAx88IHROyRUlpLpOlAvCCsLyENnUBT1CQ8YoLbjgcvD3ZvUJGqe0JPkISWUph6icYBNW6wjv4JPbAo6wdfCJg8VPs0eGtV9g1yUcQwvYeWy0NxDP0LHVbYLx7z1CL7c3z9NZMX-4u59O5oXhJesKUTFDastKKE31Si0TQpK6bqy10DQGDActmgoWRBugWpYL0cicU7K8civ4CF32_65j-NhA6tTKJQNtqz2ETVKsoqSRDeM79GIPXYZN9DldppgkgpasylTdUyaGlCJYZVynOxd8F7VrFSVqV6nqK1W5UvVTqaJZZXvqOrqVjl-HJd5LKcP-DeJ_qgPWN2mkh7o
CitedBy_id crossref_primary_10_1038_s41398_024_03222_1
crossref_primary_10_1021_acsmedchemlett_3c00059
crossref_primary_10_1111_apm_13487
crossref_primary_10_1016_j_immuni_2023_08_007
crossref_primary_10_1016_j_jmb_2025_169044
crossref_primary_10_1016_j_jbc_2025_108195
crossref_primary_10_1007_s00432_025_06097_x
crossref_primary_10_3390_ijms25126566
crossref_primary_10_1515_med_2023_0830
crossref_primary_10_1016_j_csbj_2024_02_023
crossref_primary_10_1016_j_scib_2024_03_056
crossref_primary_10_1002_pro_4729
crossref_primary_10_18632_oncotarget_28392
crossref_primary_10_3390_cancers15174246
crossref_primary_10_1016_j_ejmech_2024_116830
crossref_primary_10_1038_s41419_024_07272_7
crossref_primary_10_18632_aging_204771
crossref_primary_10_1007_s12032_024_02549_5
crossref_primary_10_3390_ijms232415944
crossref_primary_10_1038_s41392_023_01589_z
crossref_primary_10_1002_ajh_27282
crossref_primary_10_1021_acs_jmedchem_4c01217
crossref_primary_10_1248_bpb_b23_00924
crossref_primary_10_1038_s41598_024_75889_x
crossref_primary_10_1021_acs_chemrev_4c00224
crossref_primary_10_1038_s42003_024_06803_4
crossref_primary_10_1080_13543776_2024_2365410
crossref_primary_10_1016_j_jbc_2024_107616
crossref_primary_10_3389_fphar_2024_1423903
crossref_primary_10_1038_s41598_024_71687_7
crossref_primary_10_3390_genes15081015
crossref_primary_10_1073_pnas_2407159121
crossref_primary_10_1002_wrna_1822
crossref_primary_10_3802_jgo_2024_35_e64
crossref_primary_10_1080_07391102_2023_2291733
crossref_primary_10_2337_db23_0700
crossref_primary_10_1007_s10067_023_06765_8
crossref_primary_10_3389_fonc_2023_1168226
crossref_primary_10_3390_cancers15205015
crossref_primary_10_1016_j_bbrc_2024_149812
crossref_primary_10_1021_acs_jmedchem_3c00483
crossref_primary_10_1002_advs_202411642
crossref_primary_10_1016_j_ejmech_2025_117465
crossref_primary_10_1038_s41598_023_37006_2
crossref_primary_10_1016_j_bioorg_2024_107982
crossref_primary_10_3389_fimmu_2024_1396719
crossref_primary_10_1007_s11030_024_10881_1
crossref_primary_10_1093_biolre_ioaf019
crossref_primary_10_1016_j_compbiomed_2024_109304
crossref_primary_10_1016_j_dld_2023_11_003
crossref_primary_10_1016_j_canlet_2023_216116
crossref_primary_10_1021_acssynbio_3c00447
crossref_primary_10_1039_D3CP03923D
crossref_primary_10_1111_1756_185X_14761
crossref_primary_10_1038_s41419_023_06199_9
crossref_primary_10_1021_acs_jmedchem_4c02760
crossref_primary_10_1016_j_jmb_2022_167934
crossref_primary_10_1021_acs_jmedchem_4c00149
crossref_primary_10_1038_s41389_024_00529_y
crossref_primary_10_1039_D3SC00746D
Cites_doi 10.1038/onc.2012.571
10.1111/cbdd.13807
10.1016/j.ejmech.2021.113341
10.1007/s00018-004-4211-z
10.1074/jbc.M112.397885
10.1186/s12935-021-02056-x
10.1158/0008-5472.CAN-17-1510
10.1371/journal.pgen.1002050
10.1021/acs.biochem.5b01287
10.1021/acs.jcim.0c00307
10.2147/OTT.S210223
10.2174/1389557520666201127104104
10.1074/jbc.M113.450023
10.1038/74279
10.1074/jbc.M312575200
10.4049/jimmunol.181.8.5530
10.1016/S0898-6568(02)00122-5
10.1158/0008-5472.CAN-04-1923
10.1126/science.282.5397.2263
10.1016/S0065-230X(10)06002-1
10.18632/oncotarget.7577
10.1016/j.celrep.2015.08.037
10.1021/jm5006176
10.1038/nature20131
10.1016/j.jphs.2020.06.002
10.1038/modpathol.2010.205
10.1159/000505715
10.2741/3051
10.1038/cdd.2008.54
10.1158/2159-8290.CD-18-0915
10.1038/nm.3394
10.4155/fmc.14.88
10.1128/MCB.22.12.4062-4072.2002
10.1111/j.1349-7006.2009.01257.x
10.1016/S0962-8924(03)00104-1
10.4049/jimmunol.1201006
10.1016/j.bbrc.2021.05.068
10.1111/j.1600-065X.2009.00767.x
10.1074/jbc.RA120.014745
10.1128/MCB.00326-10
10.1007/BF00197421
10.1096/fj.201900698R
10.1016/j.csbj.2019.03.006
10.1152/ajpcell.00174.2009
10.1186/s12943-021-01448-x
10.2174/138161210791209027
10.1038/sj.cr.7310140
10.1681/ASN.2019101100
10.1530/JME-21-0175
10.1158/1541-7786.MCR-12-0578
10.1016/j.apsb.2018.08.009
10.3389/fphar.2021.630320
10.1016/0092-8674(93)90232-F
10.1126/science.7681217
10.1083/jcb.201204106
10.1074/jbc.M112450200
10.1016/j.ejphar.2016.11.046
10.1021/acs.biochem.1c00377
10.7150/ijbs.22209
10.1074/jbc.M115.642983
10.1016/j.febslet.2006.03.088
10.1038/s41375-018-0020-5
10.1038/s41388-019-0705-x
10.1016/S0092-8674(00)80938-1
10.1002/hep.28919
10.1038/s41388-020-01488-5
10.1038/s41598-021-99488-2
10.20892/j.issn.2095-3941.2020.0056
10.1007/s13277-015-4675-5
10.1038/nature18621
10.1016/j.bbrc.2015.12.117
10.1038/ng2078
10.1021/acs.jmedchem.8b01726
10.1038/ncb867
10.1016/j.cellsig.2007.10.002
10.1158/1078-0432.CCR-20-2718
10.1074/jbc.M200156200
10.1038/nrd.2018.21
10.1091/mbc.12.9.2711
10.1083/jcb.200710187
10.1007/978-1-4939-6762-9_2
10.1073/pnas.1508535113
10.1038/sj.onc.1206846
10.1186/1476-4598-9-126
10.1182/blood-2006-07-028829
10.15252/emmm.202114089
10.1038/s41467-018-05768-3
10.1016/j.devcel.2013.08.013
10.1158/0008-5472.CAN-15-0748
10.1002/mc.22785
10.1084/jem.193.1.101
10.4049/jimmunol.0804033
10.1016/j.ccr.2005.01.010
10.1182/blood.V97.4.911
10.1021/acs.jmedchem.0c01170
10.1074/jbc.RA119.010274
10.1016/j.immuni.2006.10.014
10.1038/s41467-021-26697-8
10.1038/s41591-018-0022-x
10.1016/j.prp.2018.04.010
10.1126/science.aaf1292
10.1097/00062752-200401000-00007
10.1074/jbc.M207536200
10.1016/j.csbj.2021.04.040
10.1128/MCB.18.7.3966
10.1128/MCB.24.12.5340-5352.2004
10.1038/ni.2703
10.1177/030006051204000605
10.1016/j.jhep.2015.03.036
10.1158/0008-5472.CAN-19-3038
10.1128/mcb.14.1.509-517.1994
10.2147/OTT.S138833
10.1016/S0167-4889(02)00322-1
10.1128/MCB.19.3.2416
10.1074/jbc.M513068200
10.1152/ajplung.00374.2009
10.1021/acsomega.0c02746
10.1097/MOH.0000000000000345
10.1016/S0968-0004(03)00091-4
10.1038/s41598-017-17604-7
10.1038/s41591-018-0014-x
10.1038/ni.2762
10.1242/dev.042820
10.1016/S0092-8674(00)00114-8
10.1074/jbc.M312498200
10.1016/j.prp.2019.01.027
10.1038/s42003-021-01969-7
10.1073/pnas.231486598
10.1021/acs.jmedchem.0c00471
10.1007/s10549-004-1002-z
10.1016/j.biopha.2013.10.012
10.1073/pnas.0405041101
10.1111/j.1365-2265.2012.04482.x
10.1016/S0092-8674(00)80252-4
10.1016/S1097-2765(04)00050-4
10.1038/nm.2645
10.1128/MCB.23.21.7875-7886.2003
10.1083/jcb.201601063
10.1038/ncomms14654
10.1111/j.1365-2559.2008.03103.x
10.18632/oncotarget.15641
10.1073/pnas.1700978114
10.1242/dev.02255
10.1016/j.pharmthera.2017.02.027
10.1016/0092-8674(93)90404-E
10.1021/acschembio.7b00980
10.1038/nri.2017.108
10.1128/MCB.00850-13
10.1016/S0021-9258(20)80562-6
10.1038/nrd.2018.201
10.2147/OTT.S222881
10.1016/j.cbpa.2020.11.007
10.1158/0008-5472.CAN-19-0343
10.1016/j.apsb.2020.07.010
10.1074/jbc.RA117.001244
10.1038/s41598-021-80999-x
10.1074/jbc.M410012200
10.3389/fchem.2020.597495
10.18632/oncotarget.12074
10.1126/sciadv.aay4458
10.1016/S0021-9258(19)50220-4
10.1152/ajpheart.00665.2011
10.1007/s00109-020-01896-w
10.1074/jbc.M006966200
10.1530/ERC-12-0313
10.1038/sj.onc.1211019
10.1158/2159-8290.CD-18-0444
10.1016/j.yjmcc.2007.09.004
10.1016/j.cell.2015.08.052
10.1002/jcp.10446
10.1128/MCB.16.12.6887
10.1371/journal.pone.0174835
10.1242/jcs.063545
10.1038/onc.2015.184
10.1074/jbc.M309964200
10.1074/jbc.M504699200
10.1128/MCB.18.10.6075
10.1016/j.phrs.2019.104595
10.1182/blood-2003-09-3287
10.1182/blood.V93.6.1809.406k35_1809_1816
10.1371/journal.pone.0256416
10.1016/j.jtho.2019.12.041
10.1038/ncomms9859
10.4049/jimmunol.173.2.945
10.1002/bies.201700247
10.1073/pnas.91.15.7335
10.1016/j.ccr.2011.03.023
10.1515/BC.2006.041
10.1186/s13058-015-0659-z
10.1016/S0021-9258(17)36874-6
10.1002/anie.201507978
10.1158/0008-5472.CAN-14-1215
10.1016/j.febslet.2010.09.016
10.1038/sj.onc.1204699
10.1038/s41556-018-0169-1
10.1016/j.imbio.2019.09.006
10.1128/MCB.05647-11
10.1073/pnas.90.15.6939
10.1016/j.jhep.2018.02.014
10.1016/j.molmed.2014.10.009
10.18632/oncotarget.3356
10.1128/MCB.24.11.4968-4978.2004
10.1016/S0969-2126(98)00027-6
10.1021/acs.jmedchem.8b00513
10.1128/MCB.19.4.3205
10.1126/science.272.5265.1170
10.1016/S0960-9822(00)00831-9
10.1016/j.jmgm.2020.107807
10.1016/j.yexcr.2009.04.011
10.1182/blood-2004-10-4057
10.3389/fonc.2021.674286
10.1016/j.bbrc.2006.10.152
10.1242/jcs.00963
10.1074/mcp.M800407-MCP200
10.1016/j.febslet.2004.07.083
10.1016/j.molcel.2011.05.014
10.1038/s41467-018-06814-w
10.1016/j.cell.2013.01.011
10.1080/2162402X.2017.1408747
10.1074/jbc.M306758200
10.1002/hep.29360
10.1074/jbc.M113.462291
10.1038/nrm2039
10.1021/acs.jmedchem.8b01725
10.1016/j.ejmg.2015.08.005
10.1158/0008-5472.CAN-20-1634
10.1007/s10753-021-01437-8
10.1016/j.ccell.2016.07.010
10.1016/j.ejmg.2005.03.001
10.1039/C8CC07813K
10.1158/1535-7163.MCT-20-0965
10.1371/journal.pone.0102847
10.1016/j.imbio.2012.01.001
10.1158/1541-7786.MCR-21-0060
10.1016/j.ejmech.2020.112117
10.1002/1521-4141(200106)31:6<1825::AID-IMMU1825>3.0.CO;2-V
10.1007/s10620-009-0924-z
10.1074/jbc.275.1.599
10.1002/jbmr.2062
10.1002/2211-5463.12493
10.1182/blood-2008-12-195792
10.1158/1541-7786.MCR-20-0165
10.1016/j.bmc.2017.10.025
10.18632/oncotarget.3323
10.1016/j.cbpa.2017.05.016
10.1128/MCB.17.9.5499
10.1074/jbc.M210552200
10.1038/ng772
10.1074/jbc.270.7.2897
10.1006/bbrc.2000.2234
10.1038/srep20471
10.1146/annurev.immunol.26.021607.090331
10.1111/jcmm.12618
10.1016/j.bbadis.2009.10.005
10.1016/j.archoralbio.2018.01.016
10.1086/499925
10.1016/j.bbrc.2003.11.070
10.1016/j.bioorg.2021.104788
10.1186/s13046-020-01818-1
10.1016/S1097-2765(00)80288-9
10.1093/emboj/16.9.2352
10.1038/ncomms3037
10.3748/wjg.v19.i4.575
10.3389/fcell.2021.630712
10.1038/ng1156
10.1186/s12964-021-00770-7
10.1158/2326-6066.CIR-19-0744
10.1074/jbc.M306461200
10.1210/en.2005-1115
10.1016/S1357-2725(98)00002-8
10.1016/j.gde.2006.12.011
10.1007/s10555-008-9126-y
10.1074/jbc.M804704200
10.1186/s12935-018-0505-3
10.1038/nature12396
10.1074/jbc.M805138200
10.1371/journal.pone.0063152
10.3390/molecules26040848
10.1083/jcb.201905085
10.1038/s41598-017-07316-3
10.1038/s41591-018-0024-8
10.1016/j.celrep.2019.05.041
10.3390/ijms20184404
10.7554/eLife.64251
10.1084/jem.20201414
10.1073/pnas.2025107118
10.1158/0008-5472.CAN-21-0548
10.3390/cancers13174309
10.1016/j.celrep.2018.06.054
10.1016/0092-8674(95)90498-0
10.1101/cshperspect.a001651
10.1371/journal.pone.0123472
10.1016/j.isci.2018.01.003
10.1038/379560a0
10.1038/s41413-018-0013-z
10.1186/1476-4598-11-72
10.1016/j.jtho.2021.08.546
10.15252/emmm.201911571
10.1016/j.celrep.2018.12.013
10.1038/nature07385
10.1038/73528
10.1182/blood.V112.11.279.279
10.1038/s41598-017-12767-9
10.1038/s41591-018-0023-9
10.1002/pro.4201
10.1101/2020.08.28.271809
10.1038/s41467-017-02351-0
10.3390/ijms20061405
10.3390/ijms18010134
10.1186/1479-5876-10-S3-P7
10.3390/cells9081798
10.1111/cpr.12721
10.1038/s41467-018-06823-9
10.1101/cshperspect.a008052
10.1136/jmg.2004.021451
ContentType Journal Article
Copyright Springer Nature Switzerland AG 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Springer Nature Switzerland AG 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2022. Springer Nature Switzerland AG.
Copyright_xml – notice: Springer Nature Switzerland AG 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: Springer Nature Switzerland AG 2022. Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2022. Springer Nature Switzerland AG.
DBID AAYXX
CITATION
K9.
7X8
DOI 10.1007/s13402-022-00698-1
DatabaseName CrossRef
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
ProQuest Health & Medical Complete (Alumni)
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2211-3436
EndPage 753
ExternalDocumentID 10_1007_s13402_022_00698_1
GrantInformation_xml – fundername: National Key Research and Development Program of China
  grantid: 2018YFE0195100
  funderid: http://dx.doi.org/10.13039/501100012166
– fundername: National Natural Science Foundation of China
  grantid: 82020108030
  funderid: http://dx.doi.org/10.13039/501100001809
GroupedDBID ---
-EM
06D
0R~
0VY
203
29~
2KG
2KM
2VQ
30V
4.4
406
408
53G
67N
8UJ
96X
AAAVM
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AAJSJ
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAYIU
AAYQN
AAYTO
AAYZH
AAZMS
ABAKF
ABDBF
ABDZT
ABECU
ABFTV
ABIPD
ABJNI
ABJOX
ABKCH
ABMQK
ABPLI
ABQBU
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABULA
ABXPI
ACAOD
ACGFS
ACHSB
ACKNC
ACMDZ
ACMLO
ACOKC
ACPIV
ACPRK
ACUHS
ACULB
ACZOJ
ADHHG
ADHIR
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFQL
AEGNC
AEJHL
AEJRE
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETCA
AEVLU
AEXYK
AFBBN
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALFXC
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMXSW
AMYLF
AMYQR
ANMIH
AOCGG
AXYYD
BGNMA
C6C
CSCUP
DDRTE
DNIVK
DPUIP
EAD
EAP
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMK
EMOBN
EPL
ESBYG
ESX
F5P
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FYJPI
GGCAI
GGRSB
GJIRD
GQ6
GQ7
H13
HF~
HMJXF
HRMNR
HZ~
I0C
IKXTQ
IMOTQ
ITM
IWAJR
J-C
JBSCW
JZLTJ
KOV
LLZTM
M4Y
NPVJJ
NQJWS
NU0
O9-
O93
O9J
P2P
PT4
R9I
RLLFE
ROL
RSV
S3A
S3B
SBL
SHX
SISQX
SJYHP
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
TSG
TUS
U2A
U9L
UG4
UOJIU
UTJUX
UZXMN
VFIZW
W48
ZMTXR
ZOVNA
~A9
AAPKM
AAYXX
ABBRH
ABDBE
ABEEZ
ABFSG
ACSTC
AEZWR
AFDZB
AFGXO
AFHIU
AFOHR
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
K9.
7X8
ID FETCH-LOGICAL-c352t-472c08f25e5c7b1f24460889fffe99cec3ea497ed0ace1a65d49634262ce13f43
IEDL.DBID U2A
ISSN 2211-3428
2211-3436
IngestDate Fri Jul 11 05:58:39 EDT 2025
Fri Jul 25 10:03:57 EDT 2025
Thu Apr 24 23:06:41 EDT 2025
Tue Jul 01 04:25:01 EDT 2025
Fri Feb 21 02:47:38 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Gab1
SHP2
PTPN11
Tyrosine phosphorylation
SHP2 inhibitors
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c352t-472c08f25e5c7b1f24460889fffe99cec3ea497ed0ace1a65d49634262ce13f43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-8746-9666
0000-0001-6771-9421
PQID 2726041527
PQPubID 2044311
PageCount 25
ParticipantIDs proquest_miscellaneous_2710969234
proquest_journals_2726041527
crossref_citationtrail_10_1007_s13402_022_00698_1
crossref_primary_10_1007_s13402_022_00698_1
springer_journals_10_1007_s13402_022_00698_1
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-10-01
PublicationDateYYYYMMDD 2022-10-01
PublicationDate_xml – month: 10
  year: 2022
  text: 2022-10-01
  day: 01
PublicationDecade 2020
PublicationPlace Dordrecht
PublicationPlace_xml – name: Dordrecht
PublicationTitle Cellular oncology (Dordrecht)
PublicationTitleAbbrev Cell Oncol
PublicationYear 2022
Publisher Springer Netherlands
Springer Nature B.V
Publisher_xml – name: Springer Netherlands
– name: Springer Nature B.V
References Grinnell, Casserly, Harrington (CR201) 2010; 298
Quilang, Liu, Forbes (CR45) 2022; 68
Yuan, Fan, Gao, Sun, Zhang, Wang, Cui, Song, Wang, Zhang, Niu (CR214) 2020; 17
Song, Lai, Chong, He, Zhang, Xue, Xie, Chen, Dong, Chen, Chen, Dai, Wan, Xiao, Cao, Liu, Wang (CR18) 2017; 8
Huang, Wang, Cao, Jiang, Li, Li, Qiu, Shen, Chang, Zhou, Pan, Lu (CR32) 2017; 7
Kwon, Ling, Maile, Badley-Clark, Clemmons (CR124) 2006; 147
Dong, Yu, Zheng, Loh, Bunting, Pauly, Huang, Zhou, Broxmeyer, Scadden, Qu (CR227) 2016; 539
Kano, Ichihara, Watanabe, Nishii, Ando, Nakasuka, Ninomiya, Kato, Kubo, Rai, Ohashi, Hotta, Tabata, Maeda, Kiura (CR276) 2021; 20
Sun, Lu, Ouyang, Lin, Zhuo, Liu, Chien, Neel, Wang (CR63) 2013; 4
Lehmann, Schmitz, Weissenbach, Sobota, Hortner, Friederichs, Behrmann, Tsiaris, Sasaki, Schneider-Mergener, Yoshimura, Neel, Heinrich, Schaper (CR71) 2003; 278
CR161
Aceto, Sausgruber, Brinkhaus, Gaidatzis, Martiny-Baron, Mazzarol, Confalonieri, Quarto, Hu, Balwierz, Pachkov, Elledge, van Nimwegen, Stadler, Bentires-Alj (CR235) 2012; 18
CR280
Schneider, Rudd (CR188) 2000; 269
Pan, Carbe, Powers, Feng, Zhang (CR157) 2010; 137
Mohi, Williams, Dearolf, Chan, Kutok, Cohen, Morgan, Boulton, Shigematsu, Keilhack, Akashi, Gilliland, Neel (CR58) 2005; 7
Matalkah, Martin, Zhao, Agazie (CR62) 2016; 18
Pan, Bao, Zhang, Wei (CR88) 2021; 11
Garg, Wahid, Khan (CR185) 2020; 225
Sarver, Acker, Bagdanoff, Chen, Chen, Chan, Firestone, Fodor, Fortanet, Hao, Hentemann, Kato, Koenig, LaBonte, Liu, Liu, Liu, McNeill, Mohseni, Sendzik, Stams, Spence, Tamez, Tichkule, Towler, Wang, Wang, Williams, Yu, LaMarche (CR294) 2019; 62
Fodor, Price, Wang, Lu, Argintaru, Chen, Glick, Hao, Kato, Koenig, LaRochelle, Liu, McNeill, Majumdar, Nishiguchi, Perez, Paris, Quinn, Ramsey, Sendzik, Shultz, Williams, Stams, Blacklow, Acker, LaMarche (CR311) 2018; 13
Loh, Vattikuti, Schubbert, Reynolds, Carlson, Lieuw, Cheng, Lee, Stokoe, Bonifas, Curtiss, Gotlib, Meshinchi, Le Beau, Emanuel, Shannon (CR224) 2004; 103
Anselmi, Calligari, Hub, Tartaglia, Bocchinfuso, Stella (CR21) 2020; 60
Han, Xiang, Sun, Liu, Sun, Wen, Shen, Wang, Chen, Wang, Cheng, Li, Wu, Cong, Feng, Ding, Wang (CR243) 2015; 63
Qu, Yu, Azzarelli, Cooper, Broxmeyer, Feng (CR118) 1998; 18
Okur, Russo, O'Bryan (CR109) 2014; 34
Tseng, Huang, Chen, Sheu, Shan, Tsai, Wang, Chen, Hsieh, Lin (CR86) 2012; 217
Nishida, Yoshida, Itoh, Fukada, Ohtani, Shirogane, Atsumi, Takahashi-Tezuka, Ishihara, Hibi, Hirano (CR101) 1999; 93
Chen, Barsoumian, Yang, Younes, Verma, Hu, Menon, Wasley, Masropour, Mosaffa, Ozgen, Klein, Cortez, Welsh (CR269) 2020; 8
Wang, Liu, Liu, Tang, Yang, Feng (CR206) 2005; 89
Yang, Xu, Wang, Song, Yu, Li, Cao, Xiong, Chen, Zhang, Zhao, Wang (CR251) 2019; 12
Geyer, Lacroix-Triki, Savage, Arnedos, Lambros, MacKay, Natrajan, Reis-Filho (CR252) 2011; 24
CR173
Lechleider, Sugimoto, Bennett, Kashishian, Cooper, Shoelson, Walsh, Neel (CR67) 1993; 268
Tocheva, Peled, Strazza, Adam, Lerrer, Nayak, Azoulay-Alfaguter, Foster, Philips, Neel, Ueberheide, Mor (CR196) 2020; 295
Alhumaid, Dasouki, Ahmed, AbalKhail, Hagos, Wakil, Hashmi (CR223) 2020; 143
Sun, Ren, Gunawan, Teng, Chen, Lawrence, Cai, Lawrence, Wu (CR287) 2018; 32
Zehender, Huang, Gyorfi, Matei, Trinh-Minh, Xu, Li, Chen, Lin, Dees, Beyer, Gelse, Zhang, Bergmann, Ramming, Birchmeier, Distler, Schett, Distler (CR39) 2018; 9
Rawlings, Rosler, Harrison (CR169) 2004; 117
Vemulapalli, Donovan, Seegar, Rogers, Bae, Lumpkin, Cao, Henke, Ray, Fischer, Cuny, Blacklow (CR318) 2021; 60
Xu, Guo, Ye, Shi, Sun, Zhang, Huang, Huang, Zeng, Zhang, Ke, Cheng (CR256) 2021; 12
Hof, Pluskey, Dhe-Paganon, Eck, Shoelson (CR2) 1998; 92
Song, Wang, Ge, Chen, Xu, Sun, Xiong (CR281) 2021; 11
Buckarma, Werneburg, Conboy, Kabashima, O'Brien, Wang, Rizvi, Smoot (CR96) 2020; 18
Wu, Xu, Li, Xu, Li, Liu, Kirby, Loh, Li, Sarafianos, Qu (CR295) 2019; 62
Keilhack, David, McGregor, Cantley, Neel (CR52) 2005; 280
Takahashi, Tsutsumi, Kikuchi, Obuse, Saito, Seidl, Karisch, Fernandez, Cho, Ohnishi, Rozenblatt-Rosen, Meyerson, Neel, Hatakeyama (CR95) 2011; 43
Yang, Wang, Moore, Liang, Dooner, Wu, Terek, Chen, Ehrlich, Quesenberry, Neel (CR142) 2013; 499
Oh, Gu, Saxton, Timms, Hausdorff, Frevert, Kahn, Pawson, Neel, Thomas (CR80) 1999; 19
CR261
Montagner, Yart, Dance, Perret, Salles, Raynal (CR149) 2005; 280
Vogel, Lammers, Huang, Ullrich (CR65) 1993; 259
Fujioka, Matozaki, Noguchi, Iwamatsu, Yamao, Takahashi, Tsuda, Takada, Kasuga (CR110) 1996; 16
Cai, Guo, Yuan, Li, Wang, Sun, Li, Gu (CR250) 2014; 68
Miyamoto, Miyamoto, Takahashi, Yomogita, Higashi, Kondo, Hatakeyama (CR234) 2008; 27
CR137
Zeng, Zhang, Yu, Li, Wu, Gunawan, Lane, Mali, Li, Chan, Kapur, Wells, Zhang (CR292) 2014; 57
Agazie, Hayman (CR61) 2003; 23
Toral, Wuenschel, Black (CR267) 2021; 16
Zheng, Liu, Wu, Yang, Wang, Zhou, Chen, Li (CR302) 2021; 110
Fiebelkow, Guendel, Guendel, Mehwald, Jetka, Komorowski, Waldherr, Schaper, Dittrich (CR68) 2021; 19
CR131
Chen, Zhu, Pei, Qiu, Xiong, Long, Lin, Lu, Xu, Wu (CR38) 2021; 20
CR253
Mullard (CR283) 2018; 17
Ren, Meng, Mei, Zhao, Jove, Wu (CR160) 2004; 279
Xia, Yang, Wu, Li, Kan, Zheng, Wang (CR277) 2021; 21
Shen, Chen, Zhu, Wu, Shen, Xi, Sun (CR307) 2020; 190
Yang, Tang, Luo, Wang, Zhou (CR278) 2017; 8
Kontaridis, Eminaga, Fornaro, Zito, Sordella, Settleman, Bennett (CR132) 2004; 24
Ahmed, Lin, Suen, Melo, Levitt, Suhling, Ladbury (CR72) 2013; 200
Fedele, Ran, Diskin, Wei, Jen, Geer, Araki, Ozerdem, Simeone, Miller, Neel, Tang (CR150) 2018; 8
Cheng, Su, Huang, Hsieh, Hu, Hung, Chang (CR203) 2010; 9
Lin, Wieteska, Suen, Kalverda, Ahmed, Ladbury (CR81) 2021; 4
Zheng, Li, Hsu, Qu (CR211) 2013; 288
Torres-Ayuso, Brognard (CR222) 2018; 8
Tripathi, Ayyannan (CR320) 2021; 97
Schlessinger (CR153) 2000; 103
Ahmadzadeh, Johnson, Heemskerk, Wunderlich, Dudley, White, Rosenberg (CR259) 2009; 114
Xiang, Cheng, Liu, Wang, Han, Sun, Li, Yang, Chen, Xia, Liu, Yin, Jin, Lee, Dong, Hu, Wang, Ding (CR141) 2017; 65
Yart, Laffargue, Mayeux, Chretien, Peres, Tonks, Roche, Payrastre, Chap, Raynal (CR165) 2001; 276
Li, Jie, Lei, Gildener-Leapman, Trivedi, Green, Kane, Ferris (CR76) 2015; 75
Dechert, Duncan, Bastien, Duff, Adam, Jirik (CR66) 1995; 96
Chemnitz, Parry, Nichols, June, Riley (CR77) 2004; 173
Xu, Qu (CR126) 2008; 13
Lee, Mungunsukh, Tutino, Marquez, Day (CR212) 2010; 123
Bentires-Alj, Paez, David, Keilhack, Halmos, Naoki, Maris, Richardson, Bardelli, Sugarbaker, Richards, Du, Girard, Minna, Loh, Fisher, Velculescu, Vogelstein, Meyerson, Sellers, Neel (CR232) 2004; 64
Wong, Zhou, Liu, Wu, Xu, Li, Xu, Schumacher, Puschhof, McFarland, Zou, Dulak, Henderson, Xu, O'Day, Rendak, Liao, Cecchi, Hembrough, Schwartz, Szeto, Rustgi, Wong, Diehl, Jensen, Graziano, Ruzzo, Fereshetian, Mertins, Carr, Beroukhim, Nakamura, Oki, Watanabe, Baba, Imamura, Catenacci, Bass (CR152) 2018; 24
Baron, Davignon (CR172) 2008; 181
Pandey, Saxena, Kapur (CR225) 2017; 24
Wang, Zhao, Fu, Zheng (CR64) 2020; 8
Schramm, Fine, Edwards, Reeb, Krenz (CR56) 2012; 302
Okazaki, Maeda, Nishimura, Kurosaki, Honjo (CR194) 2001; 98
Cunha, Morari, Guihen, Razolli, Gerhard, Nonogaki, Soares, Vassallo, Ward (CR262) 2012; 77
CR114
CR112
Yang, Dutta, Shaw (CR207) 2010; 30
CR233
Salvi, Stringaro, Brunati, Agostinelli, Arancia, Clari, Toninello (CR35) 2004; 61
Mohi, Neel (CR148) 2007; 17
Feener, Rosario, Dunn, Stancheva, Myers (CR176) 2004; 24
CR230
Burmeister, Wang, Gold, Skidgel, O'Bryan, Carnegie (CR83) 2015; 290
Qu, Shi, Shen, Tsai, Orkin, Feng (CR120) 1997; 17
Razzaque, Nishizawa, Komoike, Yagi, Furutani, Amo, Kamisago, Momma, Katayama, Nakagawa, Fujiwara, Matsushima, Mizuno, Tokuyama, Hirota, Muneuchi, Higashinakagawa, Matsuoka (CR226) 2007; 39
CR117
CR239
Ren, Wang, Xie, Hu, Chai, Ding, Tang, Xia, Dou (CR37) 2017; 796
Feng (CR123) 2007; 17
Zhang, Li, Zhao, Wang, Fan, Xu, Liu, Li, Wang (CR139) 2018; 57
Raina, Crews (CR317) 2017; 39
Yan, Zhu, Zhao, Su (CR217) 2018; 18
Higashi, Nakaya, Tsutsumi, Yokoyama, Fujii, Ishikawa, Higuchi, Takahashi, Kurashima, Teishikata, Tanaka, Azuma, Hatakeyama (CR79) 2004; 279
Herbrand, Ahmadian (CR200) 2006; 387
Xu, Yu, Zheng, Zhao, Dong, He, Liang, Lu, Fang, Gan, Xu, Zhang, Dong, Zhang, Feng (CR219) 2005; 106
CR244
Yang, Wang, Pei, Song, Xu, Feng, Wang, Luo, Hu, Qiu, Feng, Yang, Zhou, Li, Zhou (CR301) 2021; 218
Pluskey, Wandless, Walsh, Shoelson (CR23) 1995; 270
Binnewies, Roberts, Kersten, Chan, Fearon, Merad, Coussens, Gabrilovich, Ostrand-Rosenberg, Hedrick, Vonderheide, Pittet, Jain, Zou, Howcroft, Woodhouse, Weinberg, Krummel (CR254) 2018; 24
Zhou, Feng, Ma, Zhang, Wu, Du, Li, Lu, Ma, Wang (CR297) 2021; 103
Chughtai, Schimchowitsch, Lebrun, Ali (CR46) 2002; 277
Breitkopf, Yang, Begley, Kulkarni, Chiu, Turke, Lauriol, Yuan, Qi, Engelman, Hong, Kontaridis, Cantley, Perrimon, Asara (CR163) 2016; 6
An, Zhao, Hou, Zhang, Xie, Zheng, Xu, Qian, Zhou, Yu, Liu, Feng, Cao (CR145) 2006; 25
Frankson, Yu, Bai, Li, Zhang, Zhang (CR291) 2017; 77
You, Yu, Feng (CR130) 1999; 19
Ivins Zito, Kontaridis, Fornaro, Feng, Bennett (CR125) 2004; 199
Zhang, Yu, Chen, Walls, Zhang, Wu, Zhang (CR55) 2020; 295
Kazlauskas, Feng, Pawson, Valius (CR90) 1993; 90
Kim, Park, Kang (CR208) 2018; 214
Okazaki, Chikuma, Iwai, Fagarasan, Honjo (CR129) 2013; 14
Tsutsumi, Ran, Neel (CR306) 2018; 8
Deng, Zhao, Qu, Chen, Zhu, Zhang, Yuan, Jin, Liu, Wang, Chen, Huang, Yu (CR19) 2015; 6
Bunda, Burrell, Heir, Zeng, Alamsahebpour, Kano, Raught, Zhang, Zadeh, Ohh (CR168) 2015; 6
Tonks (CR282) 2006; 7
Cai, Hao, Liu (CR41) 2018; 89
Hagiwara, Miyoshi, Fukuda, Nishiyama, Ikegami, Tanimoto, Murata, Takahashi, Shimoda, Hirano, Mitamura, Ogawa (CR175) 2007; 43
CR215
Barford, Neel (CR13) 1998; 6
CR210
Li, Reed, Johnson (CR59) 2009; 315
Huang, Lerner-Marmarosh, Che, Ohta, Osawa, Yoshizumi, Glassman, Yan, Berk, Abe (CR20) 2002; 277
Batth, Papetti, Pfeiffer, Francavilla, Olsen (CR103) 2018; 16
Toure, Crews (CR313) 2016; 55
Ali, Nouhi, Chughtai, Ali (CR177) 2003; 278
CR216
Hadari, Kouhara, Lax, Schlessinger (CR74) 1998; 18
Liu, Zheng, Li, Wang, Meyerson, Yang, Neel, Qu (CR158) 2016; 113
Marengere, Waterhouse, Duncan, Mittrucker, Feng, Mak (CR186) 1996; 272
Biname, Bidaud-Meynard, Magnan, Piquet, Montibus, Ch
D Barford (698_CR13) 1998; 6
M You (698_CR179) 2001; 193
698_CR319
A Montagner (698_CR149) 2005; 280
FC Geyer (698_CR252) 2011; 24
S Du (698_CR272) 2018; 7
T Okazaki (698_CR194) 2001; 98
R Tsutsumi (698_CR306) 2018; 8
D Shen (698_CR307) 2020; 190
J Fiebelkow (698_CR68) 2021; 19
C Ivins Zito (698_CR125) 2004; 199
ML Loh (698_CR224) 2004; 103
TS Batth (698_CR103) 2018; 16
E Martin (698_CR138) 2021; 19
698_CR78
SQ Zhang (698_CR159) 2004; 13
M Valius (698_CR27) 1993; 73
JR LaRochelle (698_CR22) 2016; 55
M You (698_CR130) 1999; 19
R Tsutsumi (698_CR47) 2013; 26
H Zheng (698_CR211) 2013; 288
M Yu (698_CR273) 2021; 563
MG Mohi (698_CR58) 2005; 7
M Baron (698_CR172) 2008; 181
Z Xu (698_CR256) 2021; 12
J Jiang (698_CR30) 2013; 19
M Bentires-Alj (698_CR232) 2004; 64
M Gavrieli (698_CR128) 2003; 312
698_CR69
P Cai (698_CR250) 2014; 68
F Yang (698_CR251) 2019; 12
LF Zeng (698_CR292) 2014; 57
XD Zhou (698_CR205) 2008; 15
AH Sharpe (698_CR266) 2018; 18
J Sun (698_CR63) 2013; 4
G Chan (698_CR236) 2008; 27
T Noguchi (698_CR5) 1994; 14
M Stein-Gerlach (698_CR99) 1998; 30
X Yang (698_CR278) 2017; 8
JJ Liu (698_CR140) 2018; 69
MN Okur (698_CR213) 2012; 32
ME Bowen (698_CR229) 2011; 7
SB Breitkopf (698_CR163) 2016; 6
CY Yang (698_CR199) 2019; 38
Z Song (698_CR281) 2021; 11
KA Sheppard (698_CR191) 2004; 574
JS Kim (698_CR240) 2010; 55
S Ali (698_CR177) 2003; 278
YN Chen (698_CR279) 2016; 535
X Liu (698_CR158) 2016; 113
H Kano (698_CR276) 2021; 20
H Zhou (698_CR111) 2020; 98
W Guo (698_CR143) 2020; 144
Y Wang (698_CR249) 2021; 13
SM Schoenwaelder (698_CR133) 2000; 10
698_CR91
N Chughtai (698_CR46) 2002; 277
698_CR305
HH Lee (698_CR135) 2008; 181
C Liu (698_CR299) 2021; 27
FM Ferguson (698_CR286) 2018; 17
W Li (698_CR9) 1994; 14
Z Ahmed (698_CR72) 2013; 200
H Gu (698_CR100) 1998; 2
HL Cheng (698_CR203) 2010; 9
N Hanna (698_CR164) 2006; 580
H Wang (698_CR218) 2008; 112
DL Kerr (698_CR15) 2021; 62
XQ Ren (698_CR37) 2017; 796
CJ Wu (698_CR162) 2001; 20
CC Tsai (698_CR87) 2009; 183
Y Wang (698_CR264) 2021; 11
698_CR84
M Garg (698_CR185) 2020; 225
698_CR85
Y Song (698_CR18) 2017; 8
Y Pan (698_CR157) 2010; 137
F Matalkah (698_CR62) 2016; 18
HKW Kim (698_CR231) 2014; 29
BT Burmeister (698_CR83) 2015; 290
M Tartaglia (698_CR220) 2005; 48
M Salvi (698_CR35) 2004; 61
M Tartaglia (698_CR49) 2006; 78
S Dong (698_CR238) 2012; 40
ES Oh (698_CR80) 1999; 19
H Hanafusa (698_CR248) 2002; 4
L Zhou (698_CR297) 2021; 103
LF Zhao (698_CR181) 2016; 214
698_CR36
KM Lee (698_CR187) 1998; 282
KI Pfrepper (698_CR113) 2001; 31
RC Quilang (698_CR45) 2022; 68
A Takahashi (698_CR95) 2011; 43
TK Neklesa (698_CR316) 2017; 174
CK Qu (698_CR119) 2001; 97
M Ahmadzadeh (698_CR259) 2009; 114
ME Keir (698_CR192) 2008; 26
L Karyampudi (698_CR182) 2016; 76
CK Qu (698_CR120) 1997; 17
YH Lee (698_CR212) 2010; 123
Y Zhang (698_CR303) 2021; 12
M Wang (698_CR300) 2020; 63
E Hui (698_CR75) 2017; 355
KC Ohaegbulam (698_CR260) 2015; 21
C Schramm (698_CR56) 2012; 302
S Bunda (698_CR168) 2015; 6
698_CR190
X Zhou (698_CR241) 2008; 53
698_CR25
698_CR26
M Tartaglia (698_CR51) 2003; 34
Y Cha (698_CR82) 2010; 584
Z Songyang (698_CR97) 1993; 72
YR Hadari (698_CR74) 1998; 18
W Yang (698_CR142) 2013; 499
MA Razzaque (698_CR226) 2007; 39
A Beldi-Ferchiou (698_CR40) 2017; 12
JL Riley (698_CR193) 2009; 229
S Pluskey (698_CR23) 1995; 270
M Zhao (698_CR268) 2019; 9
MI Kontaridis (698_CR53) 2006; 281
Y Yuan (698_CR214) 2020; 17
P Torres-Ayuso (698_CR222) 2018; 8
R Frankson (698_CR291) 2017; 77
E Quintana (698_CR257) 2020; 80
TR Wu (698_CR170) 2002; 277
H Keilhack (698_CR52) 2005; 280
S Hanke (698_CR73) 2009; 8
K Nishida (698_CR101) 1999; 93
698_CR180
698_CR183
T Han (698_CR243) 2015; 63
698_CR184
K Raina (698_CR317) 2017; 39
698_CR189
H Li (698_CR271) 2017; 66
M Binnewies (698_CR254) 2018; 24
KL Grinnell (698_CR201) 2010; 298
M Toure (698_CR313) 2016; 55
S Jakob (698_CR29) 2008; 283
ZR Hartman (698_CR198) 2013; 11
VE Schneeberger (698_CR288) 2015; 6
RAP Padua (698_CR309) 2018; 9
LJ He (698_CR285) 2019; 12
YC Wang (698_CR304) 2018; 14
T Matozaki (698_CR122) 2009; 100
RKP Tripathi (698_CR320) 2021; 97
EP Feener (698_CR176) 2004; 24
LL Cunha (698_CR262) 2012; 77
H An (698_CR145) 2006; 25
I Lee (698_CR209) 2010; 1802
JT Bagdanoff (698_CR310) 2019; 62
H Ran (698_CR33) 2017; 114
698_CR48
BJ Mayer (698_CR4) 2017; 1555
RY Zhang (698_CR55) 2020; 295
698_CR173
Y Patel (698_CR44) 2016; 7
698_CR178
CK Qu (698_CR118) 1998; 18
M Marasco (698_CR24) 2021; 19
JM Chemnitz (698_CR77) 2004; 173
Q Zhao (698_CR314) 2019; 55
RZ Xu (698_CR219) 2005; 106
M Dance (698_CR147) 2008; 20
TF Gajewski (698_CR258) 2013; 14
H Schneider (698_CR188) 2000; 269
P Minooa (698_CR94) 2003; 15
GS Wong (698_CR152) 2018; 24
C Xu (698_CR134) 2019; 33
698_CR280
EH Buckarma (698_CR96) 2020; 18
698_CR161
T Araki (698_CR16) 2003; 278
RY Zhang (698_CR246) 2016; 7
Q Zhang (698_CR139) 2018; 57
NK Tonks (698_CR282) 2006; 7
S Butterworth (698_CR289) 2014; 6
698_CR7
WM Yu (698_CR144) 2003; 22
J Li (698_CR76) 2015; 75
L Dong (698_CR227) 2016; 539
X Yang (698_CR301) 2021; 218
Y Fujioka (698_CR110) 1996; 16
S Gu (698_CR315) 2018; 40
RJ Lechleider (698_CR67) 1993; 268
Q Wang (698_CR64) 2020; 8
C Fedele (698_CR150) 2018; 8
V Vemulapalli (698_CR318) 2021; 60
WT Arthur (698_CR202) 2001; 12
P-C Tseng (698_CR86) 2012; 217
JW Zheng (698_CR237) 2016; 37
MJ LaMarche (698_CR284) 2020; 63
X Sun (698_CR287) 2018; 32
D Miyamoto (698_CR234) 2008; 27
TM Saxton (698_CR115) 2000; 24
RJ Nichols (698_CR151) 2018; 20
A Kazlauskas (698_CR90) 1993; 90
EA Bard-Chapeau (698_CR174) 2011; 19
AS Tocheva (698_CR196) 2020; 295
LM Scott (698_CR17) 2010; 16
MS Alhumaid (698_CR223) 2020; 143
MR Kuhné (698_CR93) 1993; 268
ME Chen (698_CR31) 2019; 215
698_CR261
Y Ren (698_CR160) 2004; 279
R Deng (698_CR19) 2015; 6
Q Liu (698_CR308) 2020; 152
M Rosário (698_CR10) 2003; 13
S Sugimoto (698_CR98) 1994; 269
KS Grossmann (698_CR11) 2010; 106
LA Jarvis (698_CR156) 2006; 133
JS Rawlings (698_CR169) 2004; 117
CL Yu (698_CR127) 2000; 275
GS Feng (698_CR123) 2007; 17
L Xia (698_CR277) 2021; 21
BG Neel (698_CR1) 2003; 28
X Wu (698_CR171) 2012; 189
P Sarver (698_CR294) 2019; 62
MN Okur (698_CR109) 2014; 34
J Schlessinger (698_CR153) 2000; 103
CK Qu (698_CR105) 2002; 1592
M Fodor (698_CR311) 2018; 13
A Mullard (698_CR283) 2018; 17
J Bregeon (698_CR136) 2009; 297
TM Saxton (698_CR116) 1997; 16
LEM Marengere (698_CR186) 1996; 272
N Aceto (698_CR235) 2012; 18
U Lehmann (698_CR71) 2003; 278
698_CR253
698_CR131
Y Han (698_CR195) 2020; 10
H Wang (698_CR247) 2009; 284
698_CR137
PSY Chong (698_CR70) 2019; 79
Z Hartman (698_CR293) 2020; 5
D Chen (698_CR269) 2020; 8
SI Ou (698_CR312) 2020; 15
YM Agazie (698_CR61) 2003; 23
M Marasco (698_CR14) 2020; 6
L Dong (698_CR54) 2021; 9
M Tajan (698_CR6) 2015; 58
F Biname (698_CR204) 2016; 214
KJ Toral (698_CR267) 2021; 16
W Vogel (698_CR65) 1993; 259
M Zheng (698_CR302) 2021; 110
MK Kim (698_CR208) 2018; 214
S Kleffel (698_CR270) 2015; 162
CC Lin (698_CR81) 2021; 4
698_CR244
Z Hu (698_CR242) 2017; 10
M Kwon (698_CR124) 2006; 147
M Tartaglia (698_CR50) 2001; 29
W Jun (698_CR42) 2021; 11
LL Cunha (698_CR263) 2013; 20
Q Huang (698_CR20) 2002; 277
Y Cheng (698_CR43) 2020; 31
K Zhang (698_CR245) 2016; 35
W Chen (698_CR89) 2013; 152
S Noda (698_CR57) 2016; 469
JR LaRochelle (698_CR296) 2017; 25
J Zhang (698_CR221) 2015; 19
L Xia (698_CR275) 2021; 21
X Wu (698_CR295) 2019; 62
DF Quail (698_CR255) 2013; 19
YT Sun (698_CR298) 2020; 80
H Ran (698_CR290) 2016; 30
DM Xiang (698_CR141) 2017; 65
M Strazza (698_CR197) 2021; 44
698_CR230
698_CR112
698_CR233
Z Cai (698_CR41) 2018; 89
M Tartaglia (698_CR167) 2004; 11
698_CR114
XQ Yang (698_CR207) 2010; 30
M Anselmi (698_CR21) 2020; 60
J Li (698_CR59) 2009; 315
698_CR239
698_CR117
SW Chen (698_CR38) 2021; 20
JX Yu (698_CR146) 2013; 288
D Xu (698_CR126) 2008; 13
X Wu (698_CR265) 2019; 17
Z Pan (698_CR88) 2021; 11
K Miura (698_CR12) 2013; 32
FM Wang (698_CR206) 2005; 89
JC Yoo (698_CR108) 2006; 351
ZH Yu (698_CR3) 2013; 288
RJ Chan (698_CR28) 2007; 109
U Dechert (698_CR66) 1995; 96
SQ Zhang (698_CR106) 2002; 22
F Liotti (698_CR154) 2021; 40
MG Mohi (698_CR148) 2007; 17
S Bhattacharyya (698_CR166) 2018; 293
Y Hagiwara (698_CR175) 2007; 43
AM Bennett (698_CR8) 1994; 91
H Higashi (698_CR79) 2004; 279
698_CR102
698_CR104
698_CR107
A Yart (698_CR165) 2001; 276
698_CR228
U Herbrand (698_CR200) 2006; 387
A Prahallad (698_CR274) 2015; 12
H Hanafusa (698_CR155) 2004; 279
T Okazaki (698_CR129) 2013; 14
H Kouhara (698_CR92) 1997; 89
MI Kontaridis (698_CR132) 2004; 24
D Yan (698_CR217) 2018; 18
P Hof (698_CR2) 1998; 92
A Zehender (698_CR39) 2018; 9
R Pandey (698_CR225) 2017; 24
EE Zhang (698_CR121) 2004; 101
J Li (698_CR34) 2014; 9
698_CR210
Y Huang (698_CR32) 2017; 7
698_CR215
H Chen (698_CR60) 2020; 39
698_CR216
References_xml – ident: CR173
– volume: 32
  start-page: 5292
  year: 2013
  end-page: 5301
  ident: CR12
  article-title: Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase
  publication-title: Oncogene
  doi: 10.1038/onc.2012.571
– ident: CR230
– volume: 97
  start-page: 721
  year: 2021
  end-page: 773
  ident: CR320
  article-title: Emerging chemical scaffolds with potential SHP2 phosphatase inhibitory capabilities - A comprehensive review
  publication-title: Chem. Biol. Drug Des.
  doi: 10.1111/cbdd.13807
– volume: 218
  start-page: 113341
  year: 2021
  ident: CR301
  article-title: Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2021.113341
– volume: 61
  start-page: 2393
  year: 2004
  end-page: 2404
  ident: CR35
  article-title: Tyrosine phosphatase activity in mitochondria: presence of Shp-2 phosphatase in mitochondria
  publication-title: Cell Mol. Life Sci.
  doi: 10.1007/s00018-004-4211-z
– volume: 214
  start-page: 625
  year: 2016
  end-page: 633
  ident: CR181
  article-title: Shp2 Deficiency Impairs the Inflammatory Response Against Haemophilus influenzae by Regulating Macrophage Polarization
  publication-title: Int. J. Infect.
– volume: 288
  start-page: 3823
  year: 2013
  end-page: 3830
  ident: CR146
  article-title: Modulation of Fatty Acid Synthase Degradation by Concerted Action of p38 MAP Kinase, E3 Ligase COP1, and SH2-Tyrosine Phosphatase Shp2
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M112.397885
– volume: 21
  start-page: 337
  year: 2021
  ident: CR277
  article-title: SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness
  publication-title: Cancer Cell. Int.
  doi: 10.1186/s12935-021-02056-x
– volume: 77
  start-page: 5701
  year: 2017
  end-page: 5705
  ident: CR291
  article-title: Therapeutic targeting of oncogenic tyrosine phosphatases
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-1510
– volume: 7
  year: 2011
  ident: CR229
  article-title: Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome
  publication-title: PLoS Genet
  doi: 10.1371/journal.pgen.1002050
– ident: CR253
– volume: 55
  start-page: 2269
  year: 2016
  end-page: 2277
  ident: CR22
  article-title: Structural and functional consequences of three cancer-associated mutations of the oncogenic phosphatase SHP2
  publication-title: Biochemistry
  doi: 10.1021/acs.biochem.5b01287
– volume: 60
  start-page: 3157
  year: 2020
  end-page: 3171
  ident: CR21
  article-title: Structural determinants of phosphopeptide binding to the N-Terminal Src homology 2 domain of the SHP2 phosphatase
  publication-title: J. Chem. Inf. Model
  doi: 10.1021/acs.jcim.0c00307
– volume: 12
  start-page: 5897
  year: 2019
  end-page: 5906
  ident: CR285
  article-title: The prognostic significance of SHP2 and its binding protein hook1 in non-small cell lung cancer
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S210223
– volume: 21
  start-page: 1314
  year: 2021
  end-page: 1321
  ident: CR275
  article-title: SHP2 inhibition benefits epidermal growth factor receptor-mutated non-small cell lung cancer therapy
  publication-title: Mini Rev. Med. Chem.
  doi: 10.2174/1389557520666201127104104
– volume: 288
  start-page: 10472
  year: 2013
  end-page: 10482
  ident: CR3
  article-title: Structural and Mechanistic Insights into LEOPARD Syndrome-Associated SHP2 Mutations
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M113.450023
– volume: 24
  start-page: 420
  year: 2000
  end-page: 423
  ident: CR115
  article-title: The SH2 tyrosine phosphatase Shp2 is required for mammalian limb development
  publication-title: Nat. Genet.
  doi: 10.1038/74279
– ident: CR178
– volume: 279
  start-page: 8497
  year: 2004
  end-page: 8505
  ident: CR160
  article-title: Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M312575200
– volume: 181
  start-page: 5530
  year: 2008
  end-page: 5536
  ident: CR172
  article-title: Inhibition of IFN-gamma-induced STAT1 tyrosine phosphorylation by human CMV is mediated by SHP2
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.181.8.5530
– volume: 15
  start-page: 319
  year: 2003
  end-page: 326
  ident: CR94
  article-title: The adaptor function of SHP-2 downstream of the prolactin receptor is required for the recruitment of p29, a substrate of SHP-2
  publication-title: Cell. Signal.
  doi: 10.1016/S0898-6568(02)00122-5
– ident: CR85
– volume: 64
  start-page: 8816
  year: 2004
  end-page: 8820
  ident: CR232
  article-title: Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-04-1923
– volume: 282
  start-page: 2263
  year: 1998
  end-page: 2266
  ident: CR187
  article-title: Molecular basis of T cell inactivation by CTLA-4
  publication-title: Science
  doi: 10.1126/science.282.5397.2263
– volume: 106
  start-page: 53
  year: 2010
  end-page: 89
  ident: CR11
  article-title: The tyrosine phosphatase Shp2 in development and cancer
  publication-title: Adv Cancer Res
  doi: 10.1016/S0065-230X(10)06002-1
– volume: 7
  start-page: 18295
  year: 2016
  end-page: 18308
  ident: CR44
  article-title: A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.7577
– volume: 12
  start-page: 1978
  year: 2015
  end-page: 1985
  ident: CR274
  article-title: PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2015.08.037
– volume: 57
  start-page: 6594
  year: 2014
  end-page: 6609
  ident: CR292
  article-title: Therapeutic potential of targeting the oncogenic SHP2 phosphatase
  publication-title: J. Med. Chem.
  doi: 10.1021/jm5006176
– volume: 539
  start-page: 304
  year: 2016
  end-page: 308
  ident: CR227
  article-title: Leukaemogenic effects of Ptpn11 activating mutations in the stem cell microenvironment
  publication-title: Nature
  doi: 10.1038/nature20131
– ident: CR91
– volume: 144
  start-page: 139
  year: 2020
  end-page: 146
  ident: CR143
  article-title: Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds
  publication-title: J. Pharmacol. Sci.
  doi: 10.1016/j.jphs.2020.06.002
– volume: 24
  start-page: 209
  year: 2011
  end-page: 231
  ident: CR252
  article-title: beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2010.205
– ident: CR190
– volume: 143
  start-page: 583
  year: 2020
  end-page: 593
  ident: CR223
  article-title: Comprehensive Genomic Analysis of Noonan Syndrome and Acute Myeloid Leukemia in Adults: A Review and Future Directions
  publication-title: Acta Haematol
  doi: 10.1159/000505715
– volume: 13
  start-page: 4925
  year: 2008
  end-page: 4932
  ident: CR126
  article-title: Protein tyrosine phosphatases in the JAK/STAT pathway
  publication-title: Front. Biosci.
  doi: 10.2741/3051
– volume: 15
  start-page: 988
  year: 2008
  end-page: 996
  ident: CR205
  article-title: Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells
  publication-title: Cell Death Differ
  doi: 10.1038/cdd.2008.54
– volume: 8
  start-page: 1210
  year: 2018
  end-page: 1212
  ident: CR222
  article-title: Shipping Out MeK Inhibitor Resistance with SHP2 Inhibitors
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-0915
– volume: 19
  start-page: 1423
  year: 2013
  end-page: 1437
  ident: CR255
  article-title: Microenvironmental regulation of tumor progression and metastasis
  publication-title: Nat Med
  doi: 10.1038/nm.3394
– volume: 6
  start-page: 1423
  year: 2014
  end-page: 1437
  ident: CR289
  article-title: Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention
  publication-title: Future Med. Chem.
  doi: 10.4155/fmc.14.88
– ident: CR137
– volume: 22
  start-page: 4062
  year: 2002
  end-page: 4072
  ident: CR106
  article-title: Receptor-specific regulation of phosphatidylinositol 3'-kinase activation by the protein tyrosine phosphatase Shp2
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.22.12.4062-4072.2002
– volume: 100
  start-page: 1786
  year: 2009
  end-page: 1793
  ident: CR122
  article-title: Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation
  publication-title: Cancer Sci.
  doi: 10.1111/j.1349-7006.2009.01257.x
– ident: CR184
– volume: 13
  start-page: 328
  year: 2003
  end-page: 335
  ident: CR10
  article-title: How to make tubes: signaling by the Met receptor tyrosine kinase
  publication-title: Trends Cell Biol
  doi: 10.1016/S0962-8924(03)00104-1
– volume: 189
  start-page: 3497
  year: 2012
  end-page: 3507
  ident: CR171
  article-title: Selective sequestration of STAT1 in the cytoplasm via phosphorylated SHP-2 ameliorates murine experimental colitis
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1201006
– volume: 563
  start-page: 1
  year: 2021
  end-page: 7
  ident: CR273
  article-title: The tyrosine phosphatase SHP2 promotes proliferation and oxaliplatin resistance of colon cancer cells through AKT and ERK
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2021.05.068
– volume: 229
  start-page: 114
  year: 2009
  end-page: 125
  ident: CR193
  article-title: PD-1 signaling in primary T cells
  publication-title: Immunol. Rev.
  doi: 10.1111/j.1600-065X.2009.00767.x
– volume: 295
  start-page: 18036
  year: 2020
  end-page: 18050
  ident: CR196
  article-title: Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA120.014745
– volume: 30
  start-page: 5306
  year: 2010
  end-page: 5317
  ident: CR207
  article-title: SHP2 Mediates the Localized Activation of Fyn Downstream of the alpha 6 beta 4 Integrin To Promote Carcinoma Invasion
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.00326-10
– volume: 96
  start-page: 609
  year: 1995
  end-page: 615
  ident: CR66
  article-title: Protein-tyrosine phosphatase SH-PTP2 (PTPN111 is localized to 12q24.1–24.3
  publication-title: Hum Genet
  doi: 10.1007/BF00197421
– volume: 33
  start-page: 11706
  year: 2019
  end-page: 11720
  ident: CR134
  article-title: Protein tyrosine phosphatase 11 acts through RhoA/ROCK to regulate eosinophil accumulation in the allergic airway
  publication-title: FASEB J.
  doi: 10.1096/fj.201900698R
– volume: 17
  start-page: 661
  year: 2019
  end-page: 674
  ident: CR265
  article-title: Application of PD-1 Blockade in Cancer Immunotherapy
  publication-title: Comput. Struct. Biotechnol. J.
  doi: 10.1016/j.csbj.2019.03.006
– ident: CR69
– volume: 297
  start-page: C1062
  year: 2009
  end-page: C1070
  ident: CR136
  article-title: Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells
  publication-title: Am. J. Physiol. Cell Physiol.
  doi: 10.1152/ajpcell.00174.2009
– volume: 20
  start-page: 144
  year: 2021
  ident: CR38
  article-title: Cancer cell-derived exosomal circUSP7 induces CD8(+) T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-021-01448-x
– volume: 16
  start-page: 1843
  year: 2010
  end-page: 1862
  ident: CR17
  article-title: Targeting Protein Tyrosine Phosphatases for Anticancer Drug Discovery
  publication-title: Curr. Pharm. Des.
  doi: 10.2174/138161210791209027
– volume: 17
  start-page: 37
  year: 2007
  end-page: 41
  ident: CR123
  article-title: Shp2-mediated molecular signaling in control of embryonic stem cell self-renewal and differentiation
  publication-title: Cell Res.
  doi: 10.1038/sj.cr.7310140
– volume: 31
  start-page: 1539
  year: 2020
  end-page: 1554
  ident: CR43
  article-title: Endogenous miR-204 protects the kidney against chronic injury in hypertension and diabetes
  publication-title: J. Am. Soc. Nephrol.
  doi: 10.1681/ASN.2019101100
– volume: 68
  start-page: 99
  year: 2022
  end-page: 110
  ident: CR45
  article-title: miR-514a-3p: a novel SHP-2 regulatory miRNA that modulates human cytotrophoblast proliferation
  publication-title: J. Mol. Endocrinol.
  doi: 10.1530/JME-21-0175
– volume: 112
  start-page: 279
  year: 2008
  end-page: 279
  ident: CR218
  article-title: Constitutive Activation of SHP2 Protein Tyrosine Phosphatase Cooperates with HoxA10 Overexpression for Progression to Acute Myeloid Leukemia in a Murine Model
  publication-title: Blood
– volume: 11
  start-page: 651
  year: 2013
  end-page: 664
  ident: CR198
  article-title: The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration
  publication-title: Mol. Cancer Res.
  doi: 10.1158/1541-7786.MCR-12-0578
– volume: 9
  start-page: 304
  year: 2019
  end-page: 315
  ident: CR268
  article-title: SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2018.08.009
– volume: 12
  start-page: 630320
  year: 2021
  ident: CR303
  article-title: Isovitexin Inhibits Ginkgolic Acids-Induced Inflammation Through Downregulating SHP2 Activation
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2021.630320
– volume: 73
  start-page: 321
  year: 1993
  end-page: 334
  ident: CR27
  article-title: Phospholipase C-γ1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal
  publication-title: Cell
  doi: 10.1016/0092-8674(93)90232-F
– volume: 259
  start-page: 1611
  year: 1993
  end-page: 1614
  ident: CR65
  article-title: Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation
  publication-title: Science
  doi: 10.1126/science.7681217
– volume: 200
  start-page: 493
  year: 2013
  end-page: 504
  ident: CR72
  article-title: Grb2 controls phosphorylation of FGFR2 by inhibiting receptor kinase and Shp2 phosphatase activity
  publication-title: J. Cell. Biol.
  doi: 10.1083/jcb.201204106
– volume: 277
  start-page: 29330
  year: 2002
  end-page: 29341
  ident: CR20
  article-title: The novel role of the C-terminal region of SHP-2. Involvement of Gab1 and SHP-2 phosphatase activity in Elk-1 activation
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M112450200
– ident: CR114
– volume: 10
  start-page: 727
  year: 2020
  end-page: 742
  ident: CR195
  article-title: PD-1/PD-L1 pathway: current researches in cancer
  publication-title: Am. J. Cancer Res.
– volume: 796
  start-page: 233
  year: 2017
  end-page: 241
  ident: CR37
  article-title: Tanshinone IIA induced cell death via miR30b-p53-PTPN11/SHP2 signaling pathway in human hepatocellular carcinoma cells
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2016.11.046
– volume: 60
  start-page: 2593
  year: 2021
  end-page: 2609
  ident: CR318
  article-title: Targeted degradation of the oncogenic phosphatase SHP2
  publication-title: Biochemistry
  doi: 10.1021/acs.biochem.1c00377
– volume: 14
  start-page: 47
  year: 2018
  end-page: 56
  ident: CR304
  article-title: Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression
  publication-title: Int. J. Biol. Sci.
  doi: 10.7150/ijbs.22209
– volume: 290
  start-page: 12058
  year: 2015
  end-page: 12067
  ident: CR83
  article-title: Protein Kinase A (PKA) Phosphorylation of Shp2 Protein Inhibits Its Phosphatase Activity and Modulates Ligand Specificity
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M115.642983
– volume: 580
  start-page: 2477
  year: 2006
  end-page: 2482
  ident: CR164
  article-title: Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1
  publication-title: FEBS Lett.
  doi: 10.1016/j.febslet.2006.03.088
– volume: 32
  start-page: 1246
  year: 2018
  end-page: 1249
  ident: CR287
  article-title: Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099
  publication-title: Leukemia
  doi: 10.1038/s41375-018-0020-5
– volume: 38
  start-page: 4075
  year: 2019
  end-page: 4094
  ident: CR199
  article-title: Src and SHP2 coordinately regulate the dynamics and organization of vimentin filaments during cell migration
  publication-title: Oncogene
  doi: 10.1038/s41388-019-0705-x
– volume: 92
  start-page: 441
  year: 1998
  end-page: 450
  ident: CR2
  article-title: Crystal structure of the tyrosine phosphatase SHP-2
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)80938-1
– volume: 65
  start-page: 1566
  year: 2017
  end-page: 1580
  ident: CR141
  article-title: Shp2 promotes liver cancer stem cell expansion by augmenting beta-catenin signaling and predicts chemotherapeutic response of patients
  publication-title: Hepatology
  doi: 10.1002/hep.28919
– volume: 39
  start-page: 7166
  year: 2020
  end-page: 7180
  ident: CR60
  article-title: SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer
  publication-title: Oncogene
  doi: 10.1038/s41388-020-01488-5
– volume: 11
  start-page: 20561
  year: 2021
  ident: CR42
  article-title: Deregulation of hsa_circ_0001971/miR-186 and hsa_circ_0001874/miR-296 signaling pathways promotes the proliferation of oral squamous carcinoma cells by synergistically activating SHP2/PLK1 signals
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-021-99488-2
– volume: 17
  start-page: 707
  year: 2020
  end-page: 725
  ident: CR214
  article-title: SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability via the PI3K/AKT/GSK3beta signaling pathway
  publication-title: Cancer Biol Med
  doi: 10.20892/j.issn.2095-3941.2020.0056
– volume: 37
  start-page: 7853
  year: 2016
  end-page: 7859
  ident: CR237
  article-title: Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma
  publication-title: Tumor Biology
  doi: 10.1007/s13277-015-4675-5
– volume: 535
  start-page: 148
  year: 2016
  end-page: 152
  ident: CR279
  article-title: Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
  publication-title: Nature
  doi: 10.1038/nature18621
– volume: 469
  start-page: 1133
  year: 2016
  end-page: 1139
  ident: CR57
  article-title: Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2015.12.117
– volume: 39
  start-page: 1013
  year: 2007
  end-page: 1017
  ident: CR226
  article-title: Germline gain-of-function mutations in RAF1 cause Noonan syndrome
  publication-title: Nat Genet
  doi: 10.1038/ng2078
– volume: 62
  start-page: 1793
  year: 2019
  end-page: 1802
  ident: CR294
  article-title: 6-Amino-3-methylpyrimidinones as potent, selective, and orally efficacious SHP2 inhibitors
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b01726
– volume: 4
  start-page: 850
  year: 2002
  end-page: 858
  ident: CR248
  article-title: Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb867
– volume: 20
  start-page: 453
  year: 2008
  end-page: 459
  ident: CR147
  article-title: The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2007.10.002
– volume: 27
  start-page: 342
  year: 2021
  end-page: 354
  ident: CR299
  article-title: Combinations with allosteric SHP2 inhibitor TNO155 to block receptor Tyrosine Kinase signaling
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-20-2718
– volume: 277
  start-page: 31107
  year: 2002
  end-page: 31114
  ident: CR46
  article-title: Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M200156200
– volume: 17
  start-page: 353
  year: 2018
  end-page: 377
  ident: CR286
  article-title: Kinase inhibitors: the road ahead
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd.2018.21
– volume: 12
  start-page: 2711
  year: 2001
  end-page: 2720
  ident: CR202
  article-title: RhoA inactivation by p190RhoGAP regulates cell spreading and migration by promoting membrane protrusion and polarity
  publication-title: Mol. Biol. Cell.
  doi: 10.1091/mbc.12.9.2711
– volume: 181
  start-page: 999
  year: 2008
  end-page: 1012
  ident: CR135
  article-title: Regulation of RhoA-dependent ROCKII activation by Shp2
  publication-title: J. Cell Biol.
  doi: 10.1083/jcb.200710187
– volume: 1555
  start-page: 37
  year: 2017
  end-page: 43
  ident: CR4
  article-title: What Have We Learned from SH2 Domains?
  publication-title: Methods Mol. Biol.
  doi: 10.1007/978-1-4939-6762-9_2
– volume: 113
  start-page: 984
  year: 2016
  end-page: 989
  ident: CR158
  article-title: Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1508535113
– volume: 22
  start-page: 5995
  year: 2003
  end-page: 6004
  ident: CR144
  article-title: Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1206846
– volume: 9
  start-page: 126
  year: 2010
  ident: CR203
  article-title: Arecoline induces HA22T/VGH hepatoma cells to undergo anoikis - involvement of STAT3 and RhoA activation
  publication-title: Mol Cancer
  doi: 10.1186/1476-4598-9-126
– volume: 109
  start-page: 862
  year: 2007
  end-page: 867
  ident: CR28
  article-title: PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
  publication-title: Blood
  doi: 10.1182/blood-2006-07-028829
– volume: 13
  year: 2021
  ident: CR249
  article-title: Targeting the SHP2 phosphatase promotes vascular damage and inhibition of tumor growth
  publication-title: EMBO Mol Med
  doi: 10.15252/emmm.202114089
– volume: 9
  start-page: 3259
  year: 2018
  ident: CR39
  article-title: The tyrosine phosphatase SHP2 controls TGFbeta-induced STAT3 signaling to regulate fibroblast activation and fibrosis
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-05768-3
– volume: 26
  start-page: 658
  year: 2013
  end-page: 665
  ident: CR47
  article-title: YAP and TAZ, hippo signaling targets, act as a rheostat for nuclear SHP2 Function
  publication-title: Dev. Cell
  doi: 10.1016/j.devcel.2013.08.013
– volume: 76
  start-page: 239
  year: 2016
  end-page: 250
  ident: CR182
  article-title: PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-kappaB
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-15-0748
– volume: 57
  start-page: 619
  year: 2018
  end-page: 628
  ident: CR139
  article-title: The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway
  publication-title: Mol. Carcinog.
  doi: 10.1002/mc.22785
– volume: 193
  start-page: 101
  year: 2001
  end-page: 109
  ident: CR179
  article-title: Modulation of the Nuclear Factor kB Pathway by Shp-2 Tyrosine Phosphatase in Mediating the Induction of Interleukin (IL)-6 by IL-1 or Tumor Necrosis Factor
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.193.1.101
– volume: 183
  start-page: 856
  year: 2009
  end-page: 864
  ident: CR87
  article-title: Glycogen synthase kinase-3beta facilitates IFN-gamma-induced STAT1 activation by regulating Src homology-2 domain-containing phosphatase 2
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0804033
– ident: CR189
– volume: 7
  start-page: 179
  year: 2005
  end-page: 191
  ident: CR58
  article-title: Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations
  publication-title: Cancer Cell.
  doi: 10.1016/j.ccr.2005.01.010
– volume: 97
  start-page: 911
  year: 2001
  end-page: 914
  ident: CR119
  article-title: Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development
  publication-title: Blood
  doi: 10.1182/blood.V97.4.911
– volume: 63
  start-page: 13578
  year: 2020
  end-page: 13594
  ident: CR284
  article-title: Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.0c01170
– volume: 295
  start-page: 6187
  year: 2020
  end-page: 6201
  ident: CR55
  article-title: Mechanistic insights explain the transforming potential of the T507K substitution in the protein-tyrosine phosphatase SHP2
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA119.010274
– volume: 25
  start-page: 919
  year: 2006
  end-page: 928
  ident: CR145
  article-title: SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production
  publication-title: Immunity
  doi: 10.1016/j.immuni.2006.10.014
– volume: 12
  start-page: 6310
  year: 2021
  ident: CR256
  article-title: Endothelial deletion of SHP2 suppresses tumor angiogenesis and promotes vascular normalization
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-26697-8
– volume: 24
  start-page: 968
  year: 2018
  end-page: 977
  ident: CR152
  article-title: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0022-x
– volume: 214
  start-page: 1031
  year: 2018
  end-page: 1039
  ident: CR208
  article-title: Tumorigenic role of YAP in hepatocellular carcinogenesis is involved in SHP2 whose function is different in vitro and in vivo
  publication-title: Pathol. Res. Pract.
  doi: 10.1016/j.prp.2018.04.010
– ident: CR26
– volume: 355
  start-page: 1428
  year: 2017
  end-page: 1433
  ident: CR75
  article-title: T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
  publication-title: Science
  doi: 10.1126/science.aaf1292
– volume: 11
  start-page: 44
  year: 2004
  end-page: 50
  ident: CR167
  article-title: SHP-2 and myeloid malignancies
  publication-title: Curr. Opin. Hematol.
  doi: 10.1097/00062752-200401000-00007
– volume: 277
  start-page: 47572
  year: 2002
  end-page: 47580
  ident: CR170
  article-title: SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M207536200
– volume: 19
  start-page: 2398
  year: 2021
  end-page: 2415
  ident: CR24
  article-title: Phosphotyrosine couples peptide binding and SHP2 activation via a dynamic allosteric network
  publication-title: Comput. Struct. Biotechnol. J.
  doi: 10.1016/j.csbj.2021.04.040
– volume: 18
  start-page: 3966
  year: 1998
  end-page: 3973
  ident: CR74
  article-title: Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation
  publication-title: Mol. Cell Biol.
  doi: 10.1128/MCB.18.7.3966
– volume: 24
  start-page: 5340
  year: 2004
  end-page: 5352
  ident: CR132
  article-title: SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.24.12.5340-5352.2004
– volume: 14
  start-page: 1014
  year: 2013
  end-page: 1022
  ident: CR258
  article-title: Innate and adaptive immune cells in the tumor microenvironment
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2703
– volume: 40
  start-page: 2083
  year: 2012
  end-page: 2089
  ident: CR238
  article-title: Expression and clinical significance of SHP2 in gastric cancer
  publication-title: J Int Med Res
  doi: 10.1177/030006051204000605
– volume: 63
  start-page: 651
  year: 2015
  end-page: 660
  ident: CR243
  article-title: PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2015.03.036
– volume: 80
  start-page: 2889
  year: 2020
  end-page: 2902
  ident: CR257
  article-title: Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-19-3038
– volume: 14
  start-page: 509
  year: 1994
  end-page: 517
  ident: CR9
  article-title: A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/mcb.14.1.509-517.1994
– volume: 10
  start-page: 3881
  year: 2017
  end-page: 3891
  ident: CR242
  article-title: SHP2 overexpression enhances the invasion and metastasis of ovarian cancer in vitro and in vivo
  publication-title: Oncol. Targets Ther.
  doi: 10.2147/OTT.S138833
– ident: CR104
– volume: 1592
  start-page: 297
  year: 2002
  end-page: 301
  ident: CR105
  article-title: Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response
  publication-title: Biochim. Biophys. Acta
  doi: 10.1016/S0167-4889(02)00322-1
– volume: 19
  start-page: 2416
  year: 1999
  end-page: 2424
  ident: CR130
  article-title: Shp-2 Tyrosine Phosphatase Functions as a Negative Regulator of the Interferon-Stimulated Jak/STAT Pathway
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.19.3.2416
– volume: 281
  start-page: 6785
  year: 2006
  end-page: 6792
  ident: CR53
  article-title: PTPN11 (Shp2) Mutations in LEOPARD syndrome have dominant negative, not activating, effects
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M513068200
– volume: 298
  start-page: L361
  year: 2010
  end-page: L370
  ident: CR201
  article-title: Role of protein tyrosine phosphatase SHP2 in barrier function of pulmonary endothelium
  publication-title: Am. J. Physiol. Lung Cell Mol. Physiol.
  doi: 10.1152/ajplung.00374.2009
– volume: 5
  start-page: 25113
  year: 2020
  end-page: 25124
  ident: CR293
  article-title: Novel small-molecule inhibitor for the oncogenic tyrosine phosphatase SHP2 with anti-breast cancer cell effects
  publication-title: ACS Omega
  doi: 10.1021/acsomega.0c02746
– ident: CR161
– volume: 24
  start-page: 307
  year: 2017
  end-page: 313
  ident: CR225
  article-title: Role of SHP2 in hematopoiesis and leukemogenesis
  publication-title: Curr. Opin. Hematol.
  doi: 10.1097/MOH.0000000000000345
– volume: 28
  start-page: 284
  year: 2003
  end-page: 293
  ident: CR1
  article-title: The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
  publication-title: Trends Biochem. Sci.
  doi: 10.1016/S0968-0004(03)00091-4
– volume: 7
  start-page: 17597
  year: 2017
  ident: CR32
  article-title: SHP2 associates with nuclear localization of STAT3: significance in progression and prognosis of colorectal cancer
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-17604-7
– volume: 24
  start-page: 541
  year: 2018
  end-page: 550
  ident: CR254
  article-title: Understanding the tumor immune microenvironment (TIME) for effective therapy
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0014-x
– ident: CR48
– ident: CR319
– volume: 14
  start-page: 1212
  year: 2013
  end-page: 1218
  ident: CR129
  article-title: A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2762
– volume: 137
  start-page: 1085
  year: 2010
  end-page: 1093
  ident: CR157
  article-title: Sprouty2-modulated Kras signaling rescues Shp2 deficiency during lens and lacrimal gland development
  publication-title: Development
  doi: 10.1242/dev.042820
– volume: 103
  start-page: 211
  year: 2000
  end-page: 225
  ident: CR153
  article-title: Cell signaling by receptor tyrosine kinases
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)00114-8
– volume: 279
  start-page: 22992
  year: 2004
  end-page: 22995
  ident: CR155
  article-title: Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor sprouty
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M312498200
– volume: 215
  start-page: 801
  year: 2019
  end-page: 806
  ident: CR31
  article-title: Association of nuclear localization of SHP2 and YAP1 with unfavorable prognosis in non-small cell lung cancer
  publication-title: Pathol. Res. Pract.
  doi: 10.1016/j.prp.2019.01.027
– volume: 4
  start-page: 437
  year: 2021
  ident: CR81
  article-title: Grb2 binding induces phosphorylation-independent activation of Shp2
  publication-title: Commun. Biol.
  doi: 10.1038/s42003-021-01969-7
– volume: 98
  start-page: 13866
  year: 2001
  end-page: 13871
  ident: CR194
  article-title: PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.231486598
– volume: 63
  start-page: 7510
  year: 2020
  end-page: 7528
  ident: CR300
  article-title: Discovery of SHP2-D26 as a first, potent, and effective PROTAC degrader of SHP2 protein
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.0c00471
– volume: 89
  start-page: 5
  year: 2005
  end-page: 14
  ident: CR206
  article-title: SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1b in vivo and in vitro
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-004-1002-z
– volume: 68
  start-page: 285
  year: 2014
  end-page: 290
  ident: CR250
  article-title: Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2013.10.012
– ident: CR7
– volume: 101
  start-page: 16064
  year: 2004
  end-page: 16069
  ident: CR121
  article-title: Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.0405041101
– volume: 77
  start-page: 918
  year: 2012
  end-page: 925
  ident: CR262
  article-title: Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma
  publication-title: Clin. Endocrinol. (Oxf.)
  doi: 10.1111/j.1365-2265.2012.04482.x
– ident: CR183
– volume: 89
  start-page: 693
  year: 1997
  end-page: 702
  ident: CR92
  article-title: A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)80252-4
– volume: 13
  start-page: 341
  year: 2004
  end-page: 355
  ident: CR159
  article-title: Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment
  publication-title: Mol Cell
  doi: 10.1016/S1097-2765(04)00050-4
– volume: 18
  start-page: 529
  year: 2012
  end-page: 537
  ident: CR235
  article-title: Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop
  publication-title: Nat Med
  doi: 10.1038/nm.2645
– volume: 23
  start-page: 7875
  year: 2003
  end-page: 7886
  ident: CR61
  article-title: Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling
  publication-title: Mol. Cell Biol.
  doi: 10.1128/MCB.23.21.7875-7886.2003
– volume: 214
  start-page: 859
  year: 2016
  end-page: 873
  ident: CR204
  article-title: Cancer-associated mutations in the protrusion-targeting region of p190RhoGAP impact tumor cell migration
  publication-title: J. Cell Biol.
  doi: 10.1083/jcb.201601063
– volume: 8
  start-page: 14654
  year: 2017
  ident: CR18
  article-title: E3 ligase FBXW7 is critical for RIG-I stabilization during antiviral responses
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms14654
– volume: 53
  start-page: 389
  year: 2008
  end-page: 402
  ident: CR241
  article-title: SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis
  publication-title: Histopathology
  doi: 10.1111/j.1365-2559.2008.03103.x
– volume: 8
  start-page: 23664
  year: 2017
  end-page: 23674
  ident: CR278
  article-title: Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.15641
– volume: 114
  start-page: 4816
  year: 2017
  end-page: 4821
  ident: CR33
  article-title: Nuclear Shp2 directs normal embryo implantation via facilitating the ERalpha tyrosine phosphorylation by the Src kinase
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1700978114
– volume: 133
  start-page: 1133
  year: 2006
  end-page: 1142
  ident: CR156
  article-title: Sprouty proteins are in vivo targets of Corkscrew/SHP-2 tyrosine phosphatases
  publication-title: Development
  doi: 10.1242/dev.02255
– volume: 174
  start-page: 138
  year: 2017
  end-page: 144
  ident: CR316
  article-title: Targeted protein degradation by PROTACs
  publication-title: Pharmacol. Ther.
  doi: 10.1016/j.pharmthera.2017.02.027
– volume: 72
  start-page: 767
  year: 1993
  end-page: 778
  ident: CR97
  article-title: SH2 domains recognize specific phosphopeptide sequences
  publication-title: Cell
  doi: 10.1016/0092-8674(93)90404-E
– volume: 13
  start-page: 647
  year: 2018
  end-page: 656
  ident: CR311
  article-title: Dual allosteric inhibition of SHP2 phosphatase
  publication-title: ACS Chem. Biol.
  doi: 10.1021/acschembio.7b00980
– volume: 18
  start-page: 153
  year: 2018
  end-page: 167
  ident: CR266
  article-title: The diverse functions of the PD1 inhibitory pathway
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri.2017.108
– volume: 34
  start-page: 271
  year: 2014
  end-page: 279
  ident: CR109
  article-title: Receptor Tyrosine Kinase Ubiquitylation Involves the Dynamic Regulation of Cbl-Spry2 by Intersectin 1 and the Shp2 Tyrosine Phosphatase
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.00850-13
– volume: 268
  start-page: 21478
  year: 1993
  end-page: 21481
  ident: CR67
  article-title: Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor
  publication-title: J. Biol. Chem.
  doi: 10.1016/S0021-9258(20)80562-6
– volume: 17
  start-page: 847
  year: 2018
  end-page: 849
  ident: CR283
  article-title: Phosphatases start shedding their stigma of undruggability
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd.2018.201
– volume: 12
  start-page: 9435
  year: 2019
  end-page: 9447
  ident: CR251
  article-title: Gain-Of-Function E76K-Mutant SHP2 Promotes Cell Proliferation, Metastasis, And Tumor Growth In Glioblastoma Through Activation Of The ERK/CREB Pathway
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S222881
– volume: 62
  start-page: 1
  year: 2021
  end-page: 12
  ident: CR15
  article-title: Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment
  publication-title: Curr. Opin. Chem. Biol.
  doi: 10.1016/j.cbpa.2020.11.007
– ident: CR215
– ident: CR25
– volume: 79
  start-page: 4679
  year: 2019
  end-page: 4688
  ident: CR70
  article-title: IL6 Promotes a STAT3-PRL3 feedforward loop via SHP2 repression in multiple myeloma
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-19-0343
– volume: 11
  start-page: 13
  year: 2021
  end-page: 29
  ident: CR281
  article-title: Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2020.07.010
– volume: 293
  start-page: 11076
  year: 2018
  end-page: 11087
  ident: CR166
  article-title: Decline in arylsulfatase B expression increases EGFR expression by inhibiting the protein-tyrosine phosphatase SHP2 and activating JNK in prostate cells
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA117.001244
– volume: 11
  start-page: 1399
  year: 2021
  ident: CR264
  article-title: SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-021-80999-x
– volume: 280
  start-page: 5350
  year: 2005
  end-page: 5360
  ident: CR149
  article-title: A novel role for Gab1 and SHP2 in epidermal growth factor-induced ras activation
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M410012200
– volume: 8
  start-page: 597495
  year: 2020
  ident: CR64
  article-title: Exploring the Allosteric Mechanism of Src Homology-2 Domain-Containing Protein Tyrosine Phosphatase 2 (SHP2) by Molecular Dynamics Simulations
  publication-title: Front. Chem.
  doi: 10.3389/fchem.2020.597495
– volume: 7
  start-page: 73817
  year: 2016
  end-page: 73829
  ident: CR246
  article-title: SHP2 phosphatase as a novel therapeutic target for melanoma treatment
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.12074
– ident: CR210
– volume: 6
  start-page: eaay4458
  year: 2020
  ident: CR14
  article-title: Molecular mechanism of SHP2 activation by PD-1 stimulation
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.aay4458
– volume: 268
  start-page: 11479
  year: 1993
  end-page: 11481
  ident: CR93
  article-title: The insulin receptor substrate 1 associates with the SH2-containing phosphotyrosine phosphatase Syp
  publication-title: J. Biol. Chem.
  doi: 10.1016/S0021-9258(19)50220-4
– volume: 302
  start-page: H231
  year: 2012
  end-page: 243
  ident: CR56
  article-title: The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling
  publication-title: Am. J. Physiol. Heart Circ. Physiol.
  doi: 10.1152/ajpheart.00665.2011
– volume: 98
  start-page: 691
  year: 2020
  end-page: 705
  ident: CR111
  article-title: Leukocyte immunoglobulin-like receptor B4 protects against cardiac hypertrophy via SHP-2-dependent inhibition of the NF-kappaB pathway
  publication-title: J. Mol. Med. (Berl.)
  doi: 10.1007/s00109-020-01896-w
– volume: 276
  start-page: 8856
  year: 2001
  end-page: 8864
  ident: CR165
  article-title: A critical Role for phosphoinositide 3-kinase upstream of Gab1 and SHP2 in the activation of Ras and mitogen-activated protein kinases by epidermal growth factor
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M006966200
– volume: 20
  start-page: 103
  year: 2013
  end-page: 110
  ident: CR263
  article-title: Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation
  publication-title: Endocr. Relat. Cancer
  doi: 10.1530/ERC-12-0313
– volume: 27
  start-page: 3508
  year: 2008
  end-page: 3515
  ident: CR234
  article-title: Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1211019
– ident: CR112
– volume: 8
  start-page: 1237
  year: 2018
  end-page: 1249
  ident: CR150
  article-title: SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-0444
– volume: 43
  start-page: 710
  year: 2007
  end-page: 716
  ident: CR175
  article-title: SHP2-mediated signaling cascade through gp130 is essential for LIF-dependent I CaL, [Ca2+]i transient, and APD increase in cardiomyocytes
  publication-title: J. Mol. Cell Cardiol.
  doi: 10.1016/j.yjmcc.2007.09.004
– ident: CR36
– volume: 162
  start-page: 1242
  year: 2015
  end-page: 1256
  ident: CR270
  article-title: Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
  publication-title: Cell
  doi: 10.1016/j.cell.2015.08.052
– volume: 199
  start-page: 227
  year: 2004
  end-page: 236
  ident: CR125
  article-title: SHP-2 regulates the phosphatidylinositide 3?-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis
  publication-title: J. Cell Physiol.
  doi: 10.1002/jcp.10446
– volume: 16
  start-page: 6887
  year: 1996
  end-page: 6899
  ident: CR110
  article-title: A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.16.12.6887
– volume: 12
  start-page: e0174835
  year: 2017
  ident: CR40
  article-title: Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0174835
– volume: 123
  start-page: 1634
  year: 2010
  end-page: 1643
  ident: CR212
  article-title: Angiotensin-II-induced apoptosis requires regulation of nucleolin and Bcl-xL by SHP-2 in primary lung endothelial cells
  publication-title: J Cell Sci
  doi: 10.1242/jcs.063545
– volume: 35
  start-page: 1271
  year: 2016
  end-page: 1282
  ident: CR245
  article-title: Shp2 promotes metastasis of prostate cancer by attenuating the PAR3/PAR6/aPKC polarity protein complex and enhancing epithelial-to-mesenchymal transition
  publication-title: Oncogene
  doi: 10.1038/onc.2015.184
– volume: 279
  start-page: 17205
  year: 2004
  end-page: 17216
  ident: CR79
  article-title: Helicobacter pylori CagA induces Ras-independent morphogenetic response through SHP-2 recruitment and activation
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M309964200
– volume: 280
  start-page: 30984
  year: 2005
  end-page: 30993
  ident: CR52
  article-title: Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M504699200
– volume: 18
  start-page: 6075
  year: 1998
  end-page: 6082
  ident: CR118
  article-title: Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing Shp-2 mutant cells
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.18.10.6075
– volume: 152
  year: 2020
  ident: CR308
  article-title: Targeting SHP2 as a promising strategy for cancer immunotherapy
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2019.104595
– volume: 103
  start-page: 2325
  year: 2004
  end-page: 2331
  ident: CR224
  article-title: Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
  publication-title: Blood
  doi: 10.1182/blood-2003-09-3287
– ident: CR261
– volume: 93
  start-page: 1809
  year: 1999
  end-page: 1816
  ident: CR101
  article-title: Gab-family adapter proteins act downstream of cytokine and growth factor receptors and T- and B-cell antigen receptors
  publication-title: Blood
  doi: 10.1182/blood.V93.6.1809.406k35_1809_1816
– volume: 16
  year: 2021
  ident: CR267
  article-title: Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0256416
– ident: CR117
– volume: 15
  start-page: S15
  year: 2020
  end-page: S16
  ident: CR312
  article-title: A12 the SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: preliminary evaluation of a first-in-man phase 1 clinical trial
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2019.12.041
– volume: 6
  start-page: 8859
  year: 2015
  ident: CR168
  article-title: Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms9859
– volume: 173
  start-page: 945
  year: 2004
  end-page: 954
  ident: CR77
  article-title: SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.173.2.945
– volume: 40
  start-page: e1700247
  year: 2018
  ident: CR315
  article-title: PROTACs: An emerging targeting technique for protein degradation in drug discovery
  publication-title: BioEssays
  doi: 10.1002/bies.201700247
– volume: 91
  start-page: 7335
  year: 1994
  end-page: 7339
  ident: CR8
  article-title: Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.91.15.7335
– volume: 19
  start-page: 629
  year: 2011
  end-page: 639
  ident: CR174
  article-title: Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2011.03.023
– volume: 387
  start-page: 311
  year: 2006
  end-page: 317
  ident: CR200
  article-title: p190-RhoGAP as an integral component of the Tiam1/Rac1-induced downregulation of Rho
  publication-title: Biol Chem
  doi: 10.1515/BC.2006.041
– volume: 18
  start-page: 2
  year: 2016
  ident: CR62
  article-title: SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer
  publication-title: Breast Cancer Res.
  doi: 10.1186/s13058-015-0659-z
– volume: 269
  start-page: 13614
  year: 1994
  end-page: 13622
  ident: CR98
  article-title: Activation of the SH2-containing protein tyrosine phosphatase, SH-PTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1
  publication-title: J. Biol. Chem.
  doi: 10.1016/S0021-9258(17)36874-6
– volume: 55
  start-page: 1966
  year: 2016
  end-page: 1973
  ident: CR313
  article-title: Small-molecule PROTACS: new approaches to protein degradation
  publication-title: Angew. Chem. Int. Ed. Engl.
  doi: 10.1002/anie.201507978
– volume: 75
  start-page: 508
  year: 2015
  end-page: 518
  ident: CR76
  article-title: PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-14-1215
– volume: 584
  start-page: 4241
  year: 2010
  end-page: 4246
  ident: CR82
  article-title: SHP2 is a downstream target of ZAP70 to regulate JAK1/STAT3 and ERK signaling pathways in mouse embryonic stem cells
  publication-title: FEBS Lett.
  doi: 10.1016/j.febslet.2010.09.016
– volume: 20
  start-page: 6018
  year: 2001
  end-page: 6025
  ident: CR162
  article-title: The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1204699
– ident: CR233
– volume: 20
  start-page: 1064
  year: 2018
  end-page: 1073
  ident: CR151
  article-title: RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
  publication-title: Nat. Cell Biol.
  doi: 10.1038/s41556-018-0169-1
– volume: 16
  start-page: S46
  year: 2018
  end-page: S46
  ident: CR103
  article-title: Large-scale phosphoproteomics reveals Shp2 phosphatase-dependent regulators of Pdgf receptor signaling
  publication-title: Cell. Rep.
– volume: 225
  year: 2020
  ident: CR185
  article-title: Regulation of peripheral and central immunity: Understanding the role of Src homology 2 domain-containing tyrosine phosphatases, SHP-1 & SHP-2
  publication-title: Immunobiology
  doi: 10.1016/j.imbio.2019.09.006
– volume: 32
  start-page: 817
  year: 2012
  end-page: 825
  ident: CR213
  article-title: Intersectin 1 enhances Cbl ubiquitylation of epidermal growth factor receptor through regulation of Sprouty2-Cbl interaction
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.05647-11
– volume: 90
  start-page: 6939
  year: 1993
  end-page: 6942
  ident: CR90
  article-title: The 64-kDa protein that associates with the platelet-derived growth factor receptor beta subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.90.15.6939
– volume: 69
  start-page: 79
  year: 2018
  end-page: 88
  ident: CR140
  article-title: Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic beta-Catenin, PIK3CA and MET
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2018.02.014
– volume: 21
  start-page: 24
  year: 2015
  end-page: 33
  ident: CR260
  article-title: Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
  publication-title: Trends Mol Med
  doi: 10.1016/j.molmed.2014.10.009
– volume: 6
  start-page: 6191
  year: 2015
  end-page: 6202
  ident: CR288
  article-title: Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3356
– volume: 24
  start-page: 4968
  year: 2004
  end-page: 4978
  ident: CR176
  article-title: Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.24.11.4968-4978.2004
– ident: CR244
– volume: 6
  start-page: 249
  year: 1998
  end-page: 254
  ident: CR13
  article-title: Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2
  publication-title: Structure
  doi: 10.1016/S0969-2126(98)00027-6
– volume: 62
  start-page: 1125
  year: 2019
  end-page: 1137
  ident: CR295
  article-title: Small molecule inhibitor that stabilizes the autoinhibited conformation of the oncogenic tyrosine phosphatase SHP2
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b00513
– volume: 19
  start-page: 3205
  year: 1999
  end-page: 3215
  ident: CR80
  article-title: Regulation of early events in integrin signaling by protein tyrosine phosphatase SHP-2
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.19.4.3205
– volume: 272
  start-page: 1170
  year: 1996
  end-page: 1173
  ident: CR186
  article-title: Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4
  publication-title: Science
  doi: 10.1126/science.272.5265.1170
– ident: CR216
– volume: 10
  start-page: 1523
  year: 2000
  end-page: 1526
  ident: CR133
  article-title: The protein tyrosine phosphatase Shp-2 regulates RhoA activity
  publication-title: Curr. Biol.
  doi: 10.1016/S0960-9822(00)00831-9
– volume: 103
  start-page: 107807
  year: 2021
  ident: CR297
  article-title: Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2 (WT) and SHP2(F285S) by molecular dynamics study
  publication-title: J. Mol. Graph Model
  doi: 10.1016/j.jmgm.2020.107807
– volume: 315
  start-page: 2284
  year: 2009
  end-page: 2292
  ident: CR59
  article-title: Hepatocyte growth factor (HGF) signals through SHP2 to regulate primary mouse myoblast proliferation
  publication-title: Exp. Cell. Res.
  doi: 10.1016/j.yexcr.2009.04.011
– volume: 106
  start-page: 3142
  year: 2005
  end-page: 3149
  ident: CR219
  article-title: Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia
  publication-title: Blood
  doi: 10.1182/blood-2004-10-4057
– volume: 11
  start-page: 674286
  year: 2021
  ident: CR88
  article-title: UBE2D3 Activates SHP-2 Ubiquitination to Promote Glycolysis and Proliferation of Glioma via Regulating STAT3 Signaling Pathway
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2021.674286
– volume: 351
  start-page: 979
  year: 2006
  end-page: 985
  ident: CR108
  article-title: HSP70 binds to SHP2 and has effects on the SHP2-related EGFR/GAB1 signaling pathway
  publication-title: Biochem. Biophys. Res. Commun
  doi: 10.1016/j.bbrc.2006.10.152
– volume: 117
  start-page: 1281
  year: 2004
  end-page: 1283
  ident: CR169
  article-title: The JAK/STAT signaling pathway
  publication-title: J. Cell Sci.
  doi: 10.1242/jcs.00963
– ident: CR102
– volume: 8
  start-page: 519
  year: 2009
  end-page: 534
  ident: CR73
  article-title: The phosphotyrosine interactome of the insulin receptor family and its substrates IRS-1 and IRS-2
  publication-title: Mol. Cell Proteomics
  doi: 10.1074/mcp.M800407-MCP200
– volume: 574
  start-page: 37
  year: 2004
  end-page: 41
  ident: CR191
  article-title: PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta
  publication-title: FEBS Lett.
  doi: 10.1016/j.febslet.2004.07.083
– volume: 43
  start-page: 45
  year: 2011
  end-page: 56
  ident: CR95
  article-title: SHP2 Tyrosine Phosphatase Converts Parafibromin/Cdc73 from a Tumor Suppressor to an Oncogenic Driver
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2011.05.014
– ident: CR131
– volume: 9
  start-page: 4507
  year: 2018
  ident: CR309
  article-title: Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-06814-w
– ident: CR228
– volume: 152
  start-page: 467
  year: 2013
  end-page: 478
  ident: CR89
  article-title: Induction of Siglec-G by RNA viruses inhibits the innate immune response by promoting RIG-I degradation
  publication-title: Cell
  doi: 10.1016/j.cell.2013.01.011
– ident: CR305
– volume: 7
  year: 2018
  ident: CR272
  article-title: Blockade of Tumor-Expressed PD-1 promotes lung cancer growth
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2017.1408747
– ident: CR84
– volume: 278
  start-page: 52021
  year: 2003
  end-page: 52031
  ident: CR177
  article-title: SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M306758200
– volume: 66
  start-page: 1920
  year: 2017
  end-page: 1933
  ident: CR271
  article-title: Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1
  publication-title: Hepatology
  doi: 10.1002/hep.29360
– volume: 288
  start-page: 25727
  year: 2013
  end-page: 25738
  ident: CR211
  article-title: Induction of a Tumor-associated Activating Mutation in Protein Tyrosine Phosphatase Ptpn11 (Shp2) Enhances Mitochondrial Metabolism, Leading to Oxidative Stress and Senescence
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M113.462291
– volume: 7
  start-page: 833
  year: 2006
  end-page: 846
  ident: CR282
  article-title: Protein tyrosine phosphatases: from genes, to function, to disease
  publication-title: Nat. Rev. Mol. Cell. Biol.
  doi: 10.1038/nrm2039
– volume: 62
  start-page: 1781
  year: 2019
  end-page: 1792
  ident: CR310
  article-title: Optimization of fused bicyclic allosteric SHP2 inhibitors
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b01725
– volume: 58
  start-page: 509
  year: 2015
  end-page: 525
  ident: CR6
  article-title: SHP2 sails from physiology to pathology
  publication-title: Eur. J. Med. Genet.
  doi: 10.1016/j.ejmg.2015.08.005
– volume: 80
  start-page: 4840
  year: 2020
  end-page: 4853
  ident: CR298
  article-title: Allosteric SHP2 inhibitor, IACS-13909, overcomes EGFR-dependent and EGFR-independent resistance mechanisms toward Osimertinib
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-20-1634
– volume: 44
  start-page: 1529
  year: 2021
  end-page: 1539
  ident: CR197
  article-title: SHP2 Targets ITK Downstream of PD-1 to Inhibit T Cell Function
  publication-title: Inflammation
  doi: 10.1007/s10753-021-01437-8
– volume: 30
  start-page: 194
  year: 2016
  end-page: 196
  ident: CR290
  article-title: Sticking it to cancer with molecular glue for SHP2
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.07.010
– volume: 48
  start-page: 81
  year: 2005
  end-page: 96
  ident: CR220
  article-title: Germ-line and somatic PTPN11 mutations in human disease
  publication-title: Eur J Med Genet
  doi: 10.1016/j.ejmg.2005.03.001
– volume: 55
  start-page: 369
  year: 2019
  end-page: 372
  ident: CR314
  article-title: Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule
  publication-title: Chem. Commun. (Camb.)
  doi: 10.1039/C8CC07813K
– volume: 20
  start-page: 1653
  year: 2021
  end-page: 1662
  ident: CR276
  article-title: SHP2 inhibition enhances the effects of tyrosine kinase inhibitors in preclinical models of treatment-naive ALK-, ROS1-, or EGFR-altered non-small cell lung cancer
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-20-0965
– volume: 9
  start-page: e102847
  year: 2014
  ident: CR34
  article-title: Tyrosine phosphatase Shp2 mediates the estrogen biological action in breast cancer via interaction with the estrogen extranuclear receptor
  publication-title: PLoS. ONE
  doi: 10.1371/journal.pone.0102847
– volume: 217
  start-page: 926
  year: 2012
  end-page: 934
  ident: CR86
  article-title: Regulation of SHP2 by PTEN/AKT/GSK-3β signaling facilitates IFN-γ resistance in hyperproliferating gastric cancer
  publication-title: Immunobiology
  doi: 10.1016/j.imbio.2012.01.001
– volume: 19
  start-page: 1946
  year: 2021
  end-page: 1956
  ident: CR138
  article-title: SHP2 potentiates the oncogenic activity of beta-catenin to promote triple-negative breast cancer
  publication-title: Mol. Cancer Res.
  doi: 10.1158/1541-7786.MCR-21-0060
– volume: 190
  start-page: 112117
  year: 2020
  ident: CR307
  article-title: Therapeutic potential of targeting SHP2 in human developmental disorders and cancers
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2020.112117
– volume: 31
  start-page: 1825
  year: 2001
  end-page: 1836
  ident: CR113
  article-title: Structural and functional dissection of the cytoplasmic domain of the transmembrane adaptor protein SIT (SHP2-interacting transmembrane adaptor protein)
  publication-title: Eur. J. Immunol.
  doi: 10.1002/1521-4141(200106)31:6<1825::AID-IMMU1825>3.0.CO;2-V
– volume: 55
  start-page: 1565
  year: 2010
  end-page: 1569
  ident: CR240
  article-title: Overexpression of protein phosphatase non-receptor type 11 (PTPN11) in gastric carcinomas
  publication-title: Dig. Dis. Sci.
  doi: 10.1007/s10620-009-0924-z
– volume: 275
  start-page: 599
  year: 2000
  end-page: 604
  ident: CR127
  article-title: Cytosolic tyrosine dephosphorylation of STAT5. Potential role of SHP-2 in STAT5 regulation
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.275.1.599
– volume: 29
  start-page: 761
  year: 2014
  end-page: 769
  ident: CR231
  article-title: Targeted Disruption of Shp2 in Chondrocytes Leads to Metachondromatosis With Multiple Cartilaginous Protrusions
  publication-title: J Bone Miner
  doi: 10.1002/jbmr.2062
– volume: 8
  start-page: 1405
  year: 2018
  end-page: 1411
  ident: CR306
  article-title: Off-target inhibition by active site-targeting SHP2 inhibitors
  publication-title: FEBS Open Bio
  doi: 10.1002/2211-5463.12493
– ident: CR78
– volume: 114
  start-page: 1537
  year: 2009
  end-page: 1544
  ident: CR259
  article-title: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
  publication-title: Blood
  doi: 10.1182/blood-2008-12-195792
– volume: 18
  start-page: 1574
  year: 2020
  end-page: 1588
  ident: CR96
  article-title: The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma
  publication-title: Mol. Cancer Res.
  doi: 10.1158/1541-7786.MCR-20-0165
– ident: CR239
– volume: 25
  start-page: 6479
  year: 2017
  end-page: 6485
  ident: CR296
  article-title: Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2017.10.025
– volume: 6
  start-page: 9355
  year: 2015
  end-page: 9369
  ident: CR19
  article-title: Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3323
– volume: 39
  start-page: 46
  year: 2017
  end-page: 53
  ident: CR317
  article-title: Targeted protein knockdown using small molecule degraders
  publication-title: Curr. Opin. Chem. Biol.
  doi: 10.1016/j.cbpa.2017.05.016
– volume: 17
  start-page: 5499
  year: 1997
  end-page: 5507
  ident: CR120
  article-title: A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.17.9.5499
– volume: 278
  start-page: 661
  year: 2003
  end-page: 671
  ident: CR71
  article-title: SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M210552200
– volume: 29
  start-page: 465
  year: 2001
  end-page: 468
  ident: CR50
  article-title: Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
  publication-title: Nat. Genet.
  doi: 10.1038/ng772
– volume: 14
  start-page: 6674
  year: 1994
  end-page: 6682
  ident: CR5
  article-title: Role of SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in insulin-stimulated Ras activation
  publication-title: Mol. Cell. Biol.
– volume: 270
  start-page: 2897
  year: 1995
  end-page: 2900
  ident: CR23
  article-title: Potent stimulation of SH-PTP2 phosphatase activity by simultaneous occupancy of both SH2 domains
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.270.7.2897
– volume: 269
  start-page: 279
  year: 2000
  end-page: 283
  ident: CR188
  article-title: Tyrosine phosphatase SHP-2 binding to CTLA-4: absence of direct YVKM/YFIP motif recognition
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1006/bbrc.2000.2234
– volume: 6
  start-page: 20471
  year: 2016
  ident: CR163
  article-title: A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2
  publication-title: Sci. Rep.
  doi: 10.1038/srep20471
– volume: 26
  start-page: 677
  year: 2008
  end-page: 704
  ident: CR192
  article-title: PD-1 and its ligands in tolerance and immunity
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev.immunol.26.021607.090331
– ident: CR280
– volume: 19
  start-page: 2075
  year: 2015
  end-page: 2083
  ident: CR221
  article-title: Functions of Shp2 in cancer
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.12618
– volume: 1802
  start-page: 275
  year: 2010
  end-page: 283
  ident: CR209
  article-title: A suggested role for mitochondria in Noonan syndrome
  publication-title: Biochim. Biophys. Acta
  doi: 10.1016/j.bbadis.2009.10.005
– volume: 89
  start-page: 20
  year: 2018
  end-page: 25
  ident: CR41
  article-title: MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression
  publication-title: Arch. Oral. Biol.
  doi: 10.1016/j.archoralbio.2018.01.016
– volume: 78
  start-page: 279
  year: 2006
  end-page: 290
  ident: CR49
  article-title: Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease
  publication-title: Am. J. Hum. Genet.
  doi: 10.1086/499925
– ident: CR180
– volume: 312
  start-page: 1236
  year: 2003
  end-page: 1243
  ident: CR128
  article-title: Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2
  publication-title: Biochem. Biophys. Res. Commun
  doi: 10.1016/j.bbrc.2003.11.070
– volume: 110
  start-page: 104788
  year: 2021
  ident: CR302
  article-title: Novel PROTACs for degradation of SHP2 protein
  publication-title: Bioorg. Chem.
  doi: 10.1016/j.bioorg.2021.104788
– volume: 40
  start-page: 22
  year: 2021
  ident: CR154
  article-title: PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-020-01818-1
– volume: 2
  start-page: 729
  year: 1998
  end-page: 740
  ident: CR100
  article-title: Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation
  publication-title: Mol. Cell.
  doi: 10.1016/S1097-2765(00)80288-9
– volume: 16
  start-page: 2352
  year: 1997
  end-page: 2364
  ident: CR116
  article-title: Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2
  publication-title: EMBO J.
  doi: 10.1093/emboj/16.9.2352
– volume: 4
  start-page: 2037
  year: 2013
  ident: CR63
  article-title: Antagonism between binding site affinity and conformational dynamics tunes alternative cis-interactions within Shp2
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms3037
– volume: 19
  start-page: 575
  year: 2013
  end-page: 580
  ident: CR30
  article-title: Increased expression of tyrosine phosphatase SHP-2 in Helicobacter pylori-infected gastric cancer
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v19.i4.575
– volume: 9
  start-page: 630712
  year: 2021
  ident: CR54
  article-title: Activating mutation of SHP2 establishes a tumorigenic phonotype through cell-autonomous and non-cell-autonomous mechanisms
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2021.630712
– volume: 34
  start-page: 148
  year: 2003
  end-page: 150
  ident: CR51
  article-title: Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
  publication-title: Nat. Genet.
  doi: 10.1038/ng1156
– volume: 19
  start-page: 94
  year: 2021
  ident: CR68
  article-title: The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling
  publication-title: Cell Commun. Signal
  doi: 10.1186/s12964-021-00770-7
– volume: 8
  start-page: 883
  year: 2020
  end-page: 894
  ident: CR269
  article-title: SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-19-0744
– volume: 278
  start-page: 41677
  year: 2003
  end-page: 41684
  ident: CR16
  article-title: Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M306461200
– volume: 147
  start-page: 1458
  year: 2006
  end-page: 1465
  ident: CR124
  article-title: Recruitment of the tyrosine phosphatase Src homology 2 domain tyrosine phosphatase-2 to the p85 subunit of phosphatidylinositol-3 (PI-3) kinase is required for insulin-like growth factor-I-dependent PI-3 kinase activation in smooth muscle cells
  publication-title: Endocrinology
  doi: 10.1210/en.2005-1115
– volume: 30
  start-page: 559
  year: 1998
  end-page: 566
  ident: CR99
  article-title: SHP-2, SH2-containing protein tyrosine phosphatase-2
  publication-title: Int. J. Biochem. Cell Biol.
  doi: 10.1016/S1357-2725(98)00002-8
– volume: 17
  start-page: 23
  year: 2007
  end-page: 30
  ident: CR148
  article-title: The role of Shp2 (PTPN11) in cancer
  publication-title: Curr Opin. Genet. Dev.
  doi: 10.1016/j.gde.2006.12.011
– volume: 27
  start-page: 179
  year: 2008
  end-page: 192
  ident: CR236
  article-title: The tyrosine phosphatase Shp2 (PTPN11) in cancer
  publication-title: Cancer Metastasis Rev.
  doi: 10.1007/s10555-008-9126-y
– volume: 284
  start-page: 2549
  year: 2009
  end-page: 2567
  ident: CR247
  article-title: Constitutively Active SHP2 Cooperates with HoxA10 Overexpression to Induce Acute Myeloid Leukemia
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M804704200
– ident: CR107
– volume: 18
  start-page: 8
  year: 2018
  ident: CR217
  article-title: SHP-2 restricts apoptosis induced by chemotherapeutic agents via Parkin-dependent autophagy in cervical cancer
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-018-0505-3
– volume: 499
  start-page: 491
  year: 2013
  end-page: 495
  ident: CR142
  article-title: Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling
  publication-title: Nature
  doi: 10.1038/nature12396
– volume: 283
  start-page: 33155
  year: 2008
  end-page: 33161
  ident: CR29
  article-title: Nuclear protein tyrosine phosphatase Shp-2 is one important negative regulator of nuclear export of telomerase reverse transcriptase
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M805138200
– volume: 9
  start-page: 126
  year: 2010
  ident: 698_CR203
  publication-title: Mol Cancer
  doi: 10.1186/1476-4598-9-126
– volume: 113
  start-page: 984
  year: 2016
  ident: 698_CR158
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1508535113
– volume: 1802
  start-page: 275
  year: 2010
  ident: 698_CR209
  publication-title: Biochim. Biophys. Acta
  doi: 10.1016/j.bbadis.2009.10.005
– volume: 7
  start-page: 73817
  year: 2016
  ident: 698_CR246
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.12074
– volume: 62
  start-page: 1125
  year: 2019
  ident: 698_CR295
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b00513
– volume: 24
  start-page: 541
  year: 2018
  ident: 698_CR254
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0014-x
– volume: 106
  start-page: 3142
  year: 2005
  ident: 698_CR219
  publication-title: Blood
  doi: 10.1182/blood-2004-10-4057
– volume: 63
  start-page: 7510
  year: 2020
  ident: 698_CR300
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.0c00471
– volume: 24
  start-page: 4968
  year: 2004
  ident: 698_CR176
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.24.11.4968-4978.2004
– volume: 25
  start-page: 919
  year: 2006
  ident: 698_CR145
  publication-title: Immunity
  doi: 10.1016/j.immuni.2006.10.014
– volume: 193
  start-page: 101
  year: 2001
  ident: 698_CR179
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.193.1.101
– ident: 698_CR210
  doi: 10.1371/journal.pone.0063152
– volume: 9
  start-page: 630712
  year: 2021
  ident: 698_CR54
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2021.630712
– volume: 90
  start-page: 6939
  year: 1993
  ident: 698_CR90
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.90.15.6939
– volume: 109
  start-page: 862
  year: 2007
  ident: 698_CR28
  publication-title: Blood
  doi: 10.1182/blood-2006-07-028829
– volume: 123
  start-page: 1634
  year: 2010
  ident: 698_CR212
  publication-title: J Cell Sci
  doi: 10.1242/jcs.063545
– volume: 18
  start-page: 6075
  year: 1998
  ident: 698_CR118
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.18.10.6075
– ident: 698_CR305
  doi: 10.3390/molecules26040848
– volume: 293
  start-page: 11076
  year: 2018
  ident: 698_CR166
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA117.001244
– ident: 698_CR190
  doi: 10.1083/jcb.201905085
– volume: 12
  start-page: 9435
  year: 2019
  ident: 698_CR251
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT.S222881
– volume: 65
  start-page: 1566
  year: 2017
  ident: 698_CR141
  publication-title: Hepatology
  doi: 10.1002/hep.28919
– volume: 89
  start-page: 5
  year: 2005
  ident: 698_CR206
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-004-1002-z
– volume: 40
  start-page: 2083
  year: 2012
  ident: 698_CR238
  publication-title: J Int Med Res
  doi: 10.1177/030006051204000605
– volume: 16
  year: 2021
  ident: 698_CR267
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0256416
– ident: 698_CR85
  doi: 10.1038/s41598-017-07316-3
– volume: 38
  start-page: 4075
  year: 2019
  ident: 698_CR199
  publication-title: Oncogene
  doi: 10.1038/s41388-019-0705-x
– volume: 77
  start-page: 918
  year: 2012
  ident: 698_CR262
  publication-title: Clin. Endocrinol. (Oxf.)
  doi: 10.1111/j.1365-2265.2012.04482.x
– volume: 92
  start-page: 441
  year: 1998
  ident: 698_CR2
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)80938-1
– volume: 199
  start-page: 227
  year: 2004
  ident: 698_CR125
  publication-title: J. Cell Physiol.
  doi: 10.1002/jcp.10446
– volume: 295
  start-page: 18036
  year: 2020
  ident: 698_CR196
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA120.014745
– volume: 31
  start-page: 1825
  year: 2001
  ident: 698_CR113
  publication-title: Eur. J. Immunol.
  doi: 10.1002/1521-4141(200106)31:6<1825::AID-IMMU1825>3.0.CO;2-V
– volume: 10
  start-page: 3881
  year: 2017
  ident: 698_CR242
  publication-title: Oncol. Targets Ther.
  doi: 10.2147/OTT.S138833
– volume: 39
  start-page: 1013
  year: 2007
  ident: 698_CR226
  publication-title: Nat Genet
  doi: 10.1038/ng2078
– volume: 103
  start-page: 211
  year: 2000
  ident: 698_CR153
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)00114-8
– volume: 27
  start-page: 179
  year: 2008
  ident: 698_CR236
  publication-title: Cancer Metastasis Rev.
  doi: 10.1007/s10555-008-9126-y
– ident: 698_CR78
  doi: 10.1038/s41591-018-0024-8
– volume: 214
  start-page: 1031
  year: 2018
  ident: 698_CR208
  publication-title: Pathol. Res. Pract.
  doi: 10.1016/j.prp.2018.04.010
– volume: 27
  start-page: 342
  year: 2021
  ident: 698_CR299
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-20-2718
– volume: 9
  start-page: 304
  year: 2019
  ident: 698_CR268
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2018.08.009
– volume: 17
  start-page: 707
  year: 2020
  ident: 698_CR214
  publication-title: Cancer Biol Med
  doi: 10.20892/j.issn.2095-3941.2020.0056
– volume: 30
  start-page: 194
  year: 2016
  ident: 698_CR290
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2016.07.010
– volume: 18
  start-page: 1574
  year: 2020
  ident: 698_CR96
  publication-title: Mol. Cancer Res.
  doi: 10.1158/1541-7786.MCR-20-0165
– volume: 288
  start-page: 3823
  year: 2013
  ident: 698_CR146
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M112.397885
– volume: 214
  start-page: 859
  year: 2016
  ident: 698_CR204
  publication-title: J. Cell Biol.
  doi: 10.1083/jcb.201601063
– volume: 281
  start-page: 6785
  year: 2006
  ident: 698_CR53
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M513068200
– ident: 698_CR189
  doi: 10.1016/j.celrep.2019.05.041
– volume: 7
  start-page: 179
  year: 2005
  ident: 698_CR58
  publication-title: Cancer Cell.
  doi: 10.1016/j.ccr.2005.01.010
– volume: 20
  start-page: 1653
  year: 2021
  ident: 698_CR276
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-20-0965
– volume: 103
  start-page: 2325
  year: 2004
  ident: 698_CR224
  publication-title: Blood
  doi: 10.1182/blood-2003-09-3287
– volume: 24
  start-page: 307
  year: 2017
  ident: 698_CR225
  publication-title: Curr. Opin. Hematol.
  doi: 10.1097/MOH.0000000000000345
– volume: 162
  start-page: 1242
  year: 2015
  ident: 698_CR270
  publication-title: Cell
  doi: 10.1016/j.cell.2015.08.052
– volume: 62
  start-page: 1781
  year: 2019
  ident: 698_CR310
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b01725
– volume: 283
  start-page: 33155
  year: 2008
  ident: 698_CR29
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M805138200
– volume: 91
  start-page: 7335
  year: 1994
  ident: 698_CR8
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.91.15.7335
– volume: 34
  start-page: 148
  year: 2003
  ident: 698_CR51
  publication-title: Nat. Genet.
  doi: 10.1038/ng1156
– volume: 80
  start-page: 2889
  year: 2020
  ident: 698_CR257
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-19-3038
– volume: 302
  start-page: H231
  year: 2012
  ident: 698_CR56
  publication-title: Am. J. Physiol. Heart Circ. Physiol.
  doi: 10.1152/ajpheart.00665.2011
– volume: 19
  start-page: 629
  year: 2011
  ident: 698_CR174
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2011.03.023
– volume: 152
  start-page: 467
  year: 2013
  ident: 698_CR89
  publication-title: Cell
  doi: 10.1016/j.cell.2013.01.011
– volume: 39
  start-page: 7166
  year: 2020
  ident: 698_CR60
  publication-title: Oncogene
  doi: 10.1038/s41388-020-01488-5
– ident: 698_CR215
  doi: 10.3390/ijms20184404
– volume: 152
  year: 2020
  ident: 698_CR308
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2019.104595
– volume: 21
  start-page: 1314
  year: 2021
  ident: 698_CR275
  publication-title: Mini Rev. Med. Chem.
  doi: 10.2174/1389557520666201127104104
– volume: 351
  start-page: 979
  year: 2006
  ident: 698_CR108
  publication-title: Biochem. Biophys. Res. Commun
  doi: 10.1016/j.bbrc.2006.10.152
– volume: 103
  start-page: 107807
  year: 2021
  ident: 698_CR297
  publication-title: J. Mol. Graph Model
  doi: 10.1016/j.jmgm.2020.107807
– volume: 137
  start-page: 1085
  year: 2010
  ident: 698_CR157
  publication-title: Development
  doi: 10.1242/dev.042820
– volume: 4
  start-page: 2037
  year: 2013
  ident: 698_CR63
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms3037
– ident: 698_CR107
  doi: 10.7554/eLife.64251
– volume: 96
  start-page: 609
  year: 1995
  ident: 698_CR66
  publication-title: Hum Genet
  doi: 10.1007/BF00197421
– volume: 26
  start-page: 658
  year: 2013
  ident: 698_CR47
  publication-title: Dev. Cell
  doi: 10.1016/j.devcel.2013.08.013
– volume: 12
  start-page: 630320
  year: 2021
  ident: 698_CR303
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2021.630320
– volume: 114
  start-page: 1537
  year: 2009
  ident: 698_CR259
  publication-title: Blood
  doi: 10.1182/blood-2008-12-195792
– ident: 698_CR161
  doi: 10.1084/jem.20201414
– volume: 27
  start-page: 3508
  year: 2008
  ident: 698_CR234
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1211019
– volume: 133
  start-page: 1133
  year: 2006
  ident: 698_CR156
  publication-title: Development
  doi: 10.1242/dev.02255
– volume: 62
  start-page: 1793
  year: 2019
  ident: 698_CR294
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b01726
– ident: 698_CR25
  doi: 10.1073/pnas.2025107118
– ident: 698_CR84
  doi: 10.1158/0008-5472.CAN-21-0548
– ident: 698_CR239
  doi: 10.3390/cancers13174309
– ident: 698_CR183
  doi: 10.1016/j.celrep.2018.06.054
– volume: 17
  start-page: 23
  year: 2007
  ident: 698_CR148
  publication-title: Curr Opin. Genet. Dev.
  doi: 10.1016/j.gde.2006.12.011
– volume: 79
  start-page: 4679
  year: 2019
  ident: 698_CR70
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-19-0343
– volume: 218
  start-page: 113341
  year: 2021
  ident: 698_CR301
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2021.113341
– volume: 217
  start-page: 926
  year: 2012
  ident: 698_CR86
  publication-title: Immunobiology
  doi: 10.1016/j.imbio.2012.01.001
– volume: 8
  start-page: 519
  year: 2009
  ident: 698_CR73
  publication-title: Mol. Cell Proteomics
  doi: 10.1074/mcp.M800407-MCP200
– volume: 214
  start-page: 625
  year: 2016
  ident: 698_CR181
  publication-title: Int. J. Infect.
– volume: 22
  start-page: 5995
  year: 2003
  ident: 698_CR144
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1206846
– volume: 14
  start-page: 509
  year: 1994
  ident: 698_CR9
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/mcb.14.1.509-517.1994
– volume: 100
  start-page: 1786
  year: 2009
  ident: 698_CR122
  publication-title: Cancer Sci.
  doi: 10.1111/j.1349-7006.2009.01257.x
– volume: 20
  start-page: 453
  year: 2008
  ident: 698_CR147
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2007.10.002
– volume: 19
  start-page: 1946
  year: 2021
  ident: 698_CR138
  publication-title: Mol. Cancer Res.
  doi: 10.1158/1541-7786.MCR-21-0060
– volume: 53
  start-page: 389
  year: 2008
  ident: 698_CR241
  publication-title: Histopathology
  doi: 10.1111/j.1365-2559.2008.03103.x
– volume: 78
  start-page: 279
  year: 2006
  ident: 698_CR49
  publication-title: Am. J. Hum. Genet.
  doi: 10.1086/499925
– ident: 698_CR114
  doi: 10.1016/0092-8674(95)90498-0
– ident: 698_CR178
  doi: 10.1101/cshperspect.a001651
– volume: 189
  start-page: 3497
  year: 2012
  ident: 698_CR171
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1201006
– volume: 387
  start-page: 311
  year: 2006
  ident: 698_CR200
  publication-title: Biol Chem
  doi: 10.1515/BC.2006.041
– volume: 288
  start-page: 10472
  year: 2013
  ident: 698_CR3
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M113.450023
– volume: 15
  start-page: 988
  year: 2008
  ident: 698_CR205
  publication-title: Cell Death Differ
  doi: 10.1038/cdd.2008.54
– volume: 39
  start-page: 46
  year: 2017
  ident: 698_CR317
  publication-title: Curr. Opin. Chem. Biol.
  doi: 10.1016/j.cbpa.2017.05.016
– ident: 698_CR112
  doi: 10.1371/journal.pone.0123472
– volume: 269
  start-page: 279
  year: 2000
  ident: 698_CR188
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1006/bbrc.2000.2234
– ident: 698_CR137
  doi: 10.1016/j.isci.2018.01.003
– volume: 106
  start-page: 53
  year: 2010
  ident: 698_CR11
  publication-title: Adv Cancer Res
  doi: 10.1016/S0065-230X(10)06002-1
– volume: 18
  start-page: 3966
  year: 1998
  ident: 698_CR74
  publication-title: Mol. Cell Biol.
  doi: 10.1128/MCB.18.7.3966
– ident: 698_CR91
  doi: 10.1038/379560a0
– volume: 7
  year: 2018
  ident: 698_CR272
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2017.1408747
– volume: 97
  start-page: 721
  year: 2021
  ident: 698_CR320
  publication-title: Chem. Biol. Drug Des.
  doi: 10.1111/cbdd.13807
– volume: 19
  start-page: 94
  year: 2021
  ident: 698_CR68
  publication-title: Cell Commun. Signal
  doi: 10.1186/s12964-021-00770-7
– volume: 33
  start-page: 11706
  year: 2019
  ident: 698_CR134
  publication-title: FASEB J.
  doi: 10.1096/fj.201900698R
– volume: 44
  start-page: 1529
  year: 2021
  ident: 698_CR197
  publication-title: Inflammation
  doi: 10.1007/s10753-021-01437-8
– ident: 698_CR216
  doi: 10.1038/s41413-018-0013-z
– volume: 68
  start-page: 285
  year: 2014
  ident: 698_CR250
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2013.10.012
– ident: 698_CR69
  doi: 10.1186/1476-4598-11-72
– volume: 117
  start-page: 1281
  year: 2004
  ident: 698_CR169
  publication-title: J. Cell Sci.
  doi: 10.1242/jcs.00963
– volume: 18
  start-page: 8
  year: 2018
  ident: 698_CR217
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-018-0505-3
– volume: 563
  start-page: 1
  year: 2021
  ident: 698_CR273
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2021.05.068
– ident: 698_CR184
  doi: 10.1016/j.jtho.2021.08.546
– ident: 698_CR319
  doi: 10.15252/emmm.201911571
– volume: 19
  start-page: 3205
  year: 1999
  ident: 698_CR80
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.19.4.3205
– volume: 14
  start-page: 1212
  year: 2013
  ident: 698_CR129
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2762
– volume: 312
  start-page: 1236
  year: 2003
  ident: 698_CR128
  publication-title: Biochem. Biophys. Res. Commun
  doi: 10.1016/j.bbrc.2003.11.070
– volume: 19
  start-page: 1423
  year: 2013
  ident: 698_CR255
  publication-title: Nat Med
  doi: 10.1038/nm.3394
– volume: 32
  start-page: 5292
  year: 2013
  ident: 698_CR12
  publication-title: Oncogene
  doi: 10.1038/onc.2012.571
– volume: 37
  start-page: 7853
  year: 2016
  ident: 698_CR237
  publication-title: Tumor Biology
  doi: 10.1007/s13277-015-4675-5
– volume: 55
  start-page: 1966
  year: 2016
  ident: 698_CR313
  publication-title: Angew. Chem. Int. Ed. Engl.
  doi: 10.1002/anie.201507978
– volume: 279
  start-page: 17205
  year: 2004
  ident: 698_CR79
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M309964200
– volume: 12
  start-page: 1978
  year: 2015
  ident: 698_CR274
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2015.08.037
– ident: 698_CR48
  doi: 10.1038/s41467-018-06814-w
– volume: 72
  start-page: 767
  year: 1993
  ident: 698_CR97
  publication-title: Cell
  doi: 10.1016/0092-8674(93)90404-E
– volume: 275
  start-page: 599
  year: 2000
  ident: 698_CR127
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.275.1.599
– volume: 4
  start-page: 850
  year: 2002
  ident: 698_CR248
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb867
– volume: 12
  start-page: 5897
  year: 2019
  ident: 698_CR285
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S210223
– volume: 298
  start-page: L361
  year: 2010
  ident: 698_CR201
  publication-title: Am. J. Physiol. Lung Cell Mol. Physiol.
  doi: 10.1152/ajplung.00374.2009
– volume: 58
  start-page: 509
  year: 2015
  ident: 698_CR6
  publication-title: Eur. J. Med. Genet.
  doi: 10.1016/j.ejmg.2015.08.005
– volume: 26
  start-page: 677
  year: 2008
  ident: 698_CR192
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev.immunol.26.021607.090331
– volume: 15
  start-page: S15
  year: 2020
  ident: 698_CR312
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2019.12.041
– volume: 279
  start-page: 22992
  year: 2004
  ident: 698_CR155
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M312498200
– volume: 8
  start-page: 1405
  year: 2018
  ident: 698_CR306
  publication-title: FEBS Open Bio
  doi: 10.1002/2211-5463.12493
– volume: 35
  start-page: 1271
  year: 2016
  ident: 698_CR245
  publication-title: Oncogene
  doi: 10.1038/onc.2015.184
– volume: 93
  start-page: 1809
  year: 1999
  ident: 698_CR101
  publication-title: Blood
  doi: 10.1182/blood.V93.6.1809.406k35_1809_1816
– volume: 43
  start-page: 710
  year: 2007
  ident: 698_CR175
  publication-title: J. Mol. Cell Cardiol.
  doi: 10.1016/j.yjmcc.2007.09.004
– volume: 13
  start-page: 4925
  year: 2008
  ident: 698_CR126
  publication-title: Front. Biosci.
  doi: 10.2741/3051
– volume: 24
  start-page: 968
  year: 2018
  ident: 698_CR152
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0022-x
– volume: 63
  start-page: 651
  year: 2015
  ident: 698_CR243
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2015.03.036
– volume: 16
  start-page: 1843
  year: 2010
  ident: 698_CR17
  publication-title: Curr. Pharm. Des.
  doi: 10.2174/138161210791209027
– volume: 14
  start-page: 47
  year: 2018
  ident: 698_CR304
  publication-title: Int. J. Biol. Sci.
  doi: 10.7150/ijbs.22209
– volume: 13
  start-page: 341
  year: 2004
  ident: 698_CR159
  publication-title: Mol Cell
  doi: 10.1016/S1097-2765(04)00050-4
– volume: 229
  start-page: 114
  year: 2009
  ident: 698_CR193
  publication-title: Immunol. Rev.
  doi: 10.1111/j.1600-065X.2009.00767.x
– volume: 5
  start-page: 25113
  year: 2020
  ident: 698_CR293
  publication-title: ACS Omega
  doi: 10.1021/acsomega.0c02746
– volume: 16
  start-page: 6887
  year: 1996
  ident: 698_CR110
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.16.12.6887
– volume: 6
  start-page: 249
  year: 1998
  ident: 698_CR13
  publication-title: Structure
  doi: 10.1016/S0969-2126(98)00027-6
– volume: 13
  start-page: 328
  year: 2003
  ident: 698_CR10
  publication-title: Trends Cell Biol
  doi: 10.1016/S0962-8924(03)00104-1
– volume: 19
  start-page: 2075
  year: 2015
  ident: 698_CR221
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.12618
– volume: 68
  start-page: 99
  year: 2022
  ident: 698_CR45
  publication-title: J. Mol. Endocrinol.
  doi: 10.1530/JME-21-0175
– volume: 259
  start-page: 1611
  year: 1993
  ident: 698_CR65
  publication-title: Science
  doi: 10.1126/science.7681217
– volume: 580
  start-page: 2477
  year: 2006
  ident: 698_CR164
  publication-title: FEBS Lett.
  doi: 10.1016/j.febslet.2006.03.088
– volume: 282
  start-page: 2263
  year: 1998
  ident: 698_CR187
  publication-title: Science
  doi: 10.1126/science.282.5397.2263
– volume: 29
  start-page: 761
  year: 2014
  ident: 698_CR231
  publication-title: J Bone Miner
  doi: 10.1002/jbmr.2062
– volume: 277
  start-page: 47572
  year: 2002
  ident: 698_CR170
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M207536200
– volume: 13
  start-page: 647
  year: 2018
  ident: 698_CR311
  publication-title: ACS Chem. Biol.
  doi: 10.1021/acschembio.7b00980
– volume: 21
  start-page: 337
  year: 2021
  ident: 698_CR277
  publication-title: Cancer Cell. Int.
  doi: 10.1186/s12935-021-02056-x
– volume: 295
  start-page: 6187
  year: 2020
  ident: 698_CR55
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.RA119.010274
– volume: 24
  start-page: 420
  year: 2000
  ident: 698_CR115
  publication-title: Nat. Genet.
  doi: 10.1038/74279
– volume: 17
  start-page: 847
  year: 2018
  ident: 698_CR283
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd.2018.201
– volume: 60
  start-page: 2593
  year: 2021
  ident: 698_CR318
  publication-title: Biochemistry
  doi: 10.1021/acs.biochem.1c00377
– volume: 14
  start-page: 6674
  year: 1994
  ident: 698_CR5
  publication-title: Mol. Cell. Biol.
– volume: 17
  start-page: 5499
  year: 1997
  ident: 698_CR120
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.17.9.5499
– volume: 11
  start-page: 44
  year: 2004
  ident: 698_CR167
  publication-title: Curr. Opin. Hematol.
  doi: 10.1097/00062752-200401000-00007
– volume: 10
  start-page: 727
  year: 2020
  ident: 698_CR195
  publication-title: Am. J. Cancer Res.
– ident: 698_CR280
  doi: 10.1016/j.celrep.2018.12.013
– volume: 57
  start-page: 6594
  year: 2014
  ident: 698_CR292
  publication-title: J. Med. Chem.
  doi: 10.1021/jm5006176
– volume: 278
  start-page: 52021
  year: 2003
  ident: 698_CR177
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M306758200
– ident: 698_CR233
  doi: 10.1038/nature07385
– volume: 12
  start-page: 2711
  year: 2001
  ident: 698_CR202
  publication-title: Mol. Biol. Cell.
  doi: 10.1091/mbc.12.9.2711
– volume: 29
  start-page: 465
  year: 2001
  ident: 698_CR50
  publication-title: Nat. Genet.
  doi: 10.1038/ng772
– volume: 101
  start-page: 16064
  year: 2004
  ident: 698_CR121
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.0405041101
– volume: 34
  start-page: 271
  year: 2014
  ident: 698_CR109
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.00850-13
– volume: 110
  start-page: 104788
  year: 2021
  ident: 698_CR302
  publication-title: Bioorg. Chem.
  doi: 10.1016/j.bioorg.2021.104788
– volume: 15
  start-page: 319
  year: 2003
  ident: 698_CR94
  publication-title: Cell. Signal.
  doi: 10.1016/S0898-6568(02)00122-5
– volume: 7
  start-page: 833
  year: 2006
  ident: 698_CR282
  publication-title: Nat. Rev. Mol. Cell. Biol.
  doi: 10.1038/nrm2039
– volume: 24
  start-page: 209
  year: 2011
  ident: 698_CR252
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2010.205
– volume: 19
  start-page: 2416
  year: 1999
  ident: 698_CR130
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.19.3.2416
– volume: 6
  start-page: 20471
  year: 2016
  ident: 698_CR163
  publication-title: Sci. Rep.
  doi: 10.1038/srep20471
– volume: 66
  start-page: 1920
  year: 2017
  ident: 698_CR271
  publication-title: Hepatology
  doi: 10.1002/hep.29360
– volume: 18
  start-page: 153
  year: 2018
  ident: 698_CR266
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri.2017.108
– volume: 200
  start-page: 493
  year: 2013
  ident: 698_CR72
  publication-title: J. Cell. Biol.
  doi: 10.1083/jcb.201204106
– volume: 143
  start-page: 583
  year: 2020
  ident: 698_CR223
  publication-title: Acta Haematol
  doi: 10.1159/000505715
– volume: 2
  start-page: 729
  year: 1998
  ident: 698_CR100
  publication-title: Mol. Cell.
  doi: 10.1016/S1097-2765(00)80288-9
– volume: 11
  start-page: 651
  year: 2013
  ident: 698_CR198
  publication-title: Mol. Cancer Res.
  doi: 10.1158/1541-7786.MCR-12-0578
– volume: 14
  start-page: 1014
  year: 2013
  ident: 698_CR258
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.2703
– volume: 8
  start-page: 23664
  year: 2017
  ident: 698_CR278
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.15641
– volume: 6
  start-page: 8859
  year: 2015
  ident: 698_CR168
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms9859
– volume: 288
  start-page: 25727
  year: 2013
  ident: 698_CR211
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M113.462291
– ident: 698_CR117
  doi: 10.1038/73528
– volume: 6
  start-page: eaay4458
  year: 2020
  ident: 698_CR14
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.aay4458
– volume: 268
  start-page: 21478
  year: 1993
  ident: 698_CR67
  publication-title: J. Biol. Chem.
  doi: 10.1016/S0021-9258(20)80562-6
– volume: 183
  start-page: 856
  year: 2009
  ident: 698_CR87
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0804033
– volume: 20
  start-page: 1064
  year: 2018
  ident: 698_CR151
  publication-title: Nat. Cell Biol.
  doi: 10.1038/s41556-018-0169-1
– volume: 69
  start-page: 79
  year: 2018
  ident: 698_CR140
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2018.02.014
– volume: 4
  start-page: 437
  year: 2021
  ident: 698_CR81
  publication-title: Commun. Biol.
  doi: 10.1038/s42003-021-01969-7
– volume: 535
  start-page: 148
  year: 2016
  ident: 698_CR279
  publication-title: Nature
  doi: 10.1038/nature18621
– volume: 112
  start-page: 279
  year: 2008
  ident: 698_CR218
  publication-title: Blood
  doi: 10.1182/blood.V112.11.279.279
– volume: 60
  start-page: 3157
  year: 2020
  ident: 698_CR21
  publication-title: J. Chem. Inf. Model
  doi: 10.1021/acs.jcim.0c00307
– volume: 19
  start-page: 575
  year: 2013
  ident: 698_CR30
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v19.i4.575
– volume: 280
  start-page: 30984
  year: 2005
  ident: 698_CR52
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M504699200
– volume: 499
  start-page: 491
  year: 2013
  ident: 698_CR142
  publication-title: Nature
  doi: 10.1038/nature12396
– ident: 698_CR230
  doi: 10.1038/s41598-017-12767-9
– volume: 61
  start-page: 2393
  year: 2004
  ident: 698_CR35
  publication-title: Cell Mol. Life Sci.
  doi: 10.1007/s00018-004-4211-z
– volume: 57
  start-page: 619
  year: 2018
  ident: 698_CR139
  publication-title: Mol. Carcinog.
  doi: 10.1002/mc.22785
– volume: 12
  start-page: 6310
  year: 2021
  ident: 698_CR256
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-26697-8
– volume: 11
  start-page: 13
  year: 2021
  ident: 698_CR281
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2020.07.010
– volume: 73
  start-page: 321
  year: 1993
  ident: 698_CR27
  publication-title: Cell
  doi: 10.1016/0092-8674(93)90232-F
– volume: 20
  start-page: 6018
  year: 2001
  ident: 698_CR162
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1204699
– volume: 278
  start-page: 41677
  year: 2003
  ident: 698_CR16
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M306461200
– volume: 98
  start-page: 13866
  year: 2001
  ident: 698_CR194
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.231486598
– volume: 13
  year: 2021
  ident: 698_CR249
  publication-title: EMBO Mol Med
  doi: 10.15252/emmm.202114089
– volume: 8
  start-page: 883
  year: 2020
  ident: 698_CR269
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-19-0744
– volume: 8
  start-page: 1210
  year: 2018
  ident: 698_CR222
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-0915
– volume: 32
  start-page: 1246
  year: 2018
  ident: 698_CR287
  publication-title: Leukemia
  doi: 10.1038/s41375-018-0020-5
– volume: 7
  year: 2011
  ident: 698_CR229
  publication-title: PLoS Genet
  doi: 10.1371/journal.pgen.1002050
– volume: 80
  start-page: 4840
  year: 2020
  ident: 698_CR298
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-20-1634
– volume: 469
  start-page: 1133
  year: 2016
  ident: 698_CR57
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2015.12.117
– volume: 20
  start-page: 144
  year: 2021
  ident: 698_CR38
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-021-01448-x
– volume: 28
  start-page: 284
  year: 2003
  ident: 698_CR1
  publication-title: Trends Biochem. Sci.
  doi: 10.1016/S0968-0004(03)00091-4
– volume: 574
  start-page: 37
  year: 2004
  ident: 698_CR191
  publication-title: FEBS Lett.
  doi: 10.1016/j.febslet.2004.07.083
– volume: 48
  start-page: 81
  year: 2005
  ident: 698_CR220
  publication-title: Eur J Med Genet
  doi: 10.1016/j.ejmg.2005.03.001
– volume: 147
  start-page: 1458
  year: 2006
  ident: 698_CR124
  publication-title: Endocrinology
  doi: 10.1210/en.2005-1115
– volume: 181
  start-page: 999
  year: 2008
  ident: 698_CR135
  publication-title: J. Cell Biol.
  doi: 10.1083/jcb.200710187
– volume: 31
  start-page: 1539
  year: 2020
  ident: 698_CR43
  publication-title: J. Am. Soc. Nephrol.
  doi: 10.1681/ASN.2019101100
– volume: 17
  start-page: 37
  year: 2007
  ident: 698_CR123
  publication-title: Cell Res.
  doi: 10.1038/sj.cr.7310140
– ident: 698_CR244
  doi: 10.1038/s41591-018-0023-9
– volume: 62
  start-page: 1
  year: 2021
  ident: 698_CR15
  publication-title: Curr. Opin. Chem. Biol.
  doi: 10.1016/j.cbpa.2020.11.007
– ident: 698_CR102
  doi: 10.1002/pro.4201
– volume: 89
  start-page: 20
  year: 2018
  ident: 698_CR41
  publication-title: Arch. Oral. Biol.
  doi: 10.1016/j.archoralbio.2018.01.016
– volume: 173
  start-page: 945
  year: 2004
  ident: 698_CR77
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.173.2.945
– volume: 76
  start-page: 239
  year: 2016
  ident: 698_CR182
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-15-0748
– volume: 89
  start-page: 693
  year: 1997
  ident: 698_CR92
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)80252-4
– ident: 698_CR26
  doi: 10.1101/2020.08.28.271809
– volume: 21
  start-page: 24
  year: 2015
  ident: 698_CR260
  publication-title: Trends Mol Med
  doi: 10.1016/j.molmed.2014.10.009
– volume: 1555
  start-page: 37
  year: 2017
  ident: 698_CR4
  publication-title: Methods Mol. Biol.
  doi: 10.1007/978-1-4939-6762-9_2
– volume: 277
  start-page: 29330
  year: 2002
  ident: 698_CR20
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M112450200
– volume: 17
  start-page: 353
  year: 2018
  ident: 698_CR286
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd.2018.21
– volume: 18
  start-page: 2
  year: 2016
  ident: 698_CR62
  publication-title: Breast Cancer Res.
  doi: 10.1186/s13058-015-0659-z
– volume: 796
  start-page: 233
  year: 2017
  ident: 698_CR37
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2016.11.046
– volume: 40
  start-page: 22
  year: 2021
  ident: 698_CR154
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-020-01818-1
– volume: 16
  start-page: S46
  year: 2018
  ident: 698_CR103
  publication-title: Cell. Rep.
– volume: 270
  start-page: 2897
  year: 1995
  ident: 698_CR23
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.270.7.2897
– ident: 698_CR36
  doi: 10.1038/s41467-017-02351-0
– volume: 98
  start-page: 691
  year: 2020
  ident: 698_CR111
  publication-title: J. Mol. Med. (Berl.)
  doi: 10.1007/s00109-020-01896-w
– volume: 9
  start-page: 3259
  year: 2018
  ident: 698_CR39
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-05768-3
– volume: 43
  start-page: 45
  year: 2011
  ident: 698_CR95
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2011.05.014
– volume: 11
  start-page: 20561
  year: 2021
  ident: 698_CR42
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-021-99488-2
– ident: 698_CR261
  doi: 10.3390/ijms20061405
– volume: 97
  start-page: 911
  year: 2001
  ident: 698_CR119
  publication-title: Blood
  doi: 10.1182/blood.V97.4.911
– volume: 32
  start-page: 817
  year: 2012
  ident: 698_CR213
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.05647-11
– volume: 9
  start-page: e102847
  year: 2014
  ident: 698_CR34
  publication-title: PLoS. ONE
  doi: 10.1371/journal.pone.0102847
– volume: 22
  start-page: 4062
  year: 2002
  ident: 698_CR106
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.22.12.4062-4072.2002
– volume: 174
  start-page: 138
  year: 2017
  ident: 698_CR316
  publication-title: Pharmacol. Ther.
  doi: 10.1016/j.pharmthera.2017.02.027
– volume: 114
  start-page: 4816
  year: 2017
  ident: 698_CR33
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.1700978114
– volume: 30
  start-page: 559
  year: 1998
  ident: 698_CR99
  publication-title: Int. J. Biochem. Cell Biol.
  doi: 10.1016/S1357-2725(98)00002-8
– volume: 190
  start-page: 112117
  year: 2020
  ident: 698_CR307
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2020.112117
– ident: 698_CR173
  doi: 10.3390/ijms18010134
– ident: 698_CR131
  doi: 10.1186/1479-5876-10-S3-P7
– volume: 10
  start-page: 1523
  year: 2000
  ident: 698_CR133
  publication-title: Curr. Biol.
  doi: 10.1016/S0960-9822(00)00831-9
– volume: 277
  start-page: 31107
  year: 2002
  ident: 698_CR46
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M200156200
– ident: 698_CR104
  doi: 10.3390/cells9081798
– volume: 181
  start-page: 5530
  year: 2008
  ident: 698_CR172
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.181.8.5530
– volume: 16
  start-page: 2352
  year: 1997
  ident: 698_CR116
  publication-title: EMBO J.
  doi: 10.1093/emboj/16.9.2352
– volume: 584
  start-page: 4241
  year: 2010
  ident: 698_CR82
  publication-title: FEBS Lett.
  doi: 10.1016/j.febslet.2010.09.016
– volume: 355
  start-page: 1428
  year: 2017
  ident: 698_CR75
  publication-title: Science
  doi: 10.1126/science.aaf1292
– volume: 55
  start-page: 2269
  year: 2016
  ident: 698_CR22
  publication-title: Biochemistry
  doi: 10.1021/acs.biochem.5b01287
– volume: 11
  start-page: 674286
  year: 2021
  ident: 698_CR88
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2021.674286
– volume: 284
  start-page: 2549
  year: 2009
  ident: 698_CR247
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M804704200
– volume: 64
  start-page: 8816
  year: 2004
  ident: 698_CR232
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-04-1923
– ident: 698_CR180
  doi: 10.1111/cpr.12721
– volume: 55
  start-page: 369
  year: 2019
  ident: 698_CR314
  publication-title: Chem. Commun. (Camb.)
  doi: 10.1039/C8CC07813K
– volume: 18
  start-page: 529
  year: 2012
  ident: 698_CR235
  publication-title: Nat Med
  doi: 10.1038/nm.2645
– volume: 272
  start-page: 1170
  year: 1996
  ident: 698_CR186
  publication-title: Science
  doi: 10.1126/science.272.5265.1170
– volume: 1592
  start-page: 297
  year: 2002
  ident: 698_CR105
  publication-title: Biochim. Biophys. Acta
  doi: 10.1016/S0167-4889(02)00322-1
– volume: 6
  start-page: 6191
  year: 2015
  ident: 698_CR288
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3356
– volume: 77
  start-page: 5701
  year: 2017
  ident: 698_CR291
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-1510
– volume: 8
  start-page: 14654
  year: 2017
  ident: 698_CR18
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms14654
– volume: 30
  start-page: 5306
  year: 2010
  ident: 698_CR207
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.00326-10
– volume: 40
  start-page: e1700247
  year: 2018
  ident: 698_CR315
  publication-title: BioEssays
  doi: 10.1002/bies.201700247
– volume: 6
  start-page: 1423
  year: 2014
  ident: 698_CR289
  publication-title: Future Med. Chem.
  doi: 10.4155/fmc.14.88
– volume: 7
  start-page: 18295
  year: 2016
  ident: 698_CR44
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.7577
– volume: 276
  start-page: 8856
  year: 2001
  ident: 698_CR165
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M006966200
– volume: 24
  start-page: 5340
  year: 2004
  ident: 698_CR132
  publication-title: Mol. Cell. Biol.
  doi: 10.1128/MCB.24.12.5340-5352.2004
– volume: 9
  start-page: 4507
  year: 2018
  ident: 698_CR309
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-06814-w
– volume: 55
  start-page: 1565
  year: 2010
  ident: 698_CR240
  publication-title: Dig. Dis. Sci.
  doi: 10.1007/s10620-009-0924-z
– volume: 11
  start-page: 1399
  year: 2021
  ident: 698_CR264
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-021-80999-x
– volume: 279
  start-page: 8497
  year: 2004
  ident: 698_CR160
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M312575200
– volume: 225
  year: 2020
  ident: 698_CR185
  publication-title: Immunobiology
  doi: 10.1016/j.imbio.2019.09.006
– volume: 23
  start-page: 7875
  year: 2003
  ident: 698_CR61
  publication-title: Mol. Cell Biol.
  doi: 10.1128/MCB.23.21.7875-7886.2003
– ident: 698_CR7
  doi: 10.1038/s41467-018-06823-9
– volume: 144
  start-page: 139
  year: 2020
  ident: 698_CR143
  publication-title: J. Pharmacol. Sci.
  doi: 10.1016/j.jphs.2020.06.002
– volume: 297
  start-page: C1062
  year: 2009
  ident: 698_CR136
  publication-title: Am. J. Physiol. Cell Physiol.
  doi: 10.1152/ajpcell.00174.2009
– volume: 20
  start-page: 103
  year: 2013
  ident: 698_CR263
  publication-title: Endocr. Relat. Cancer
  doi: 10.1530/ERC-12-0313
– volume: 315
  start-page: 2284
  year: 2009
  ident: 698_CR59
  publication-title: Exp. Cell. Res.
  doi: 10.1016/j.yexcr.2009.04.011
– volume: 268
  start-page: 11479
  year: 1993
  ident: 698_CR93
  publication-title: J. Biol. Chem.
  doi: 10.1016/S0021-9258(19)50220-4
– volume: 539
  start-page: 304
  year: 2016
  ident: 698_CR227
  publication-title: Nature
  doi: 10.1038/nature20131
– ident: 698_CR253
  doi: 10.1101/cshperspect.a008052
– volume: 280
  start-page: 5350
  year: 2005
  ident: 698_CR149
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M410012200
– volume: 215
  start-page: 801
  year: 2019
  ident: 698_CR31
  publication-title: Pathol. Res. Pract.
  doi: 10.1016/j.prp.2019.01.027
– volume: 278
  start-page: 661
  year: 2003
  ident: 698_CR71
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M210552200
– volume: 25
  start-page: 6479
  year: 2017
  ident: 698_CR296
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2017.10.025
– volume: 8
  start-page: 597495
  year: 2020
  ident: 698_CR64
  publication-title: Front. Chem.
  doi: 10.3389/fchem.2020.597495
– volume: 7
  start-page: 17597
  year: 2017
  ident: 698_CR32
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-17604-7
– volume: 75
  start-page: 508
  year: 2015
  ident: 698_CR76
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-14-1215
– volume: 290
  start-page: 12058
  year: 2015
  ident: 698_CR83
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M115.642983
– volume: 269
  start-page: 13614
  year: 1994
  ident: 698_CR98
  publication-title: J. Biol. Chem.
  doi: 10.1016/S0021-9258(17)36874-6
– ident: 698_CR228
  doi: 10.1136/jmg.2004.021451
– volume: 19
  start-page: 2398
  year: 2021
  ident: 698_CR24
  publication-title: Comput. Struct. Biotechnol. J.
  doi: 10.1016/j.csbj.2021.04.040
– volume: 63
  start-page: 13578
  year: 2020
  ident: 698_CR284
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.0c01170
– volume: 17
  start-page: 661
  year: 2019
  ident: 698_CR265
  publication-title: Comput. Struct. Biotechnol. J.
  doi: 10.1016/j.csbj.2019.03.006
– volume: 6
  start-page: 9355
  year: 2015
  ident: 698_CR19
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.3323
– volume: 8
  start-page: 1237
  year: 2018
  ident: 698_CR150
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-18-0444
– volume: 12
  start-page: e0174835
  year: 2017
  ident: 698_CR40
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0174835
SSID ssj0000461656
Score 2.5521505
SecondaryResourceType review_article
Snippet Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein tyrosine phosphatase ubiquitously expressed mainly in the cytoplasm...
Abstract Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein tyrosine phosphatase ubiquitously expressed mainly in the...
SourceID proquest
crossref
springer
SourceType Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 729
SubjectTerms 1-Phosphatidylinositol 3-kinase
AKT protein
Allosteric properties
Antineoplastic drugs
Antitumor agents
Biomedical and Life Sciences
Biomedicine
Cancer
Cancer Research
Cell differentiation
Cell migration
Cell signaling
Cytokines
Cytoplasm
Developmental disabilities
Extracellular signal-regulated kinase
Growth factors
Homology
Kinases
miRNA
Oncology
Pathology
PD-1 protein
Phosphatase
Protein-tyrosine-phosphatase
Solid tumors
SUMO protein
Therapeutic targets
Tumor suppressor genes
Ubiquitination
Title A comprehensive review of SHP2 and its role in cancer
URI https://link.springer.com/article/10.1007/s13402-022-00698-1
https://www.proquest.com/docview/2726041527
https://www.proquest.com/docview/2710969234
Volume 45
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1NS8NAEB1si-BF_MRoLSt400Cz2U2aYyitRVEELdRTSDa7WJBU2vTgv3cmHw2KCh5DNhuYnc28yb55A3CJeI3cVtiuDmJbJJrbsZSJjUjW75tkoIxDxcn3D95kKm5nclYVha1qtnt9JFl8qZtiN1cQWxaTJ5LXxdynBR2JuTv59ZSHmz8rJCHuFW1bOSeNPgTYVbXMz9N8jUgNzPx2MloEnPEe7FZIkYXl0u7Dls4OYLvsHflxCDJkRAdf6teSgs7KIhS2MOxp8shZnKVsnq8Y0QfZPGOKlnd5BNPx6Hk4saseCLZCaJTbwueqPzBcaqn8xDEYjT1iJhljdBAorVwdi8DXaT9W2ok9mQrcUiQzj5euEe4xtLNFpk-AaTdJRYLww2AmKgMZCE8PMFr3ExOIOA0scGo7RKoSCKc-FW9RI21MtovQdlFhu8ix4GrzzHspj_Hn6G5t3qjaKquI-5hSEYzwLbjY3EYnp5OLONOLNY1xMNVCLCosuK6XpZni9zee_m_4Gexw8oyCrNeFdr5c63MEHXnSg05483I36kFr6A17hcd9Augiyu0
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8NAEB60RfQiPjFadQVvGmiS3TyORSy1tkVoC72FZLOLBUmlTQ_-e2fyaFBU8Biy2cDsbOab7DffANwiXiO35aajgsjksbLNSIjYRCTrtXXsS21RcfJw5PamvD8Ts7IobFWx3asjyfxLXRe7OZzYspg8kbwu5j7b0PSF66N3Nzud_ri_-bdCIuJu3rjVtkmlDyF2WS_z80RfY1INNL-djeYhp3sA-yVWZJ1icQ9hS6VHsFN0j_w4BtFhRAhfqteChM6KMhS20Gzce7FZlCZsnq0YEQjZPGWSFnh5AtPu4-ShZ5ZdEEyJ4CgzuWfLtq9toYT0YktjPHaJm6S1VkEglXRUxANPJe1IKityRcJxU5HQPF46mjun0EgXqToDppw44TECEI25qAhEwF3lY7xuxzrgURIYYFV2CGUpEU6dKt7CWtyYbBei7cLcdqFlwN3mmfdCIOPP0a3KvGG5WVah7WFSRUDCM-BmcxvdnM4uolQt1jTGwmQL0Sg34L5alnqK3994_r_h17DbmwwH4eBp9HwBezZ5SU7da0EjW67VJUKQLL4qPe4T7bPMuw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8NAEB60ongRnxituoI3DW02u0lzLGqpr1LQQm8h2exiQdLSpgf_vTN5tCoqeAzZbGB2NvNN9ptvAC4Qr5HbCtvVQWSLWHM7kjK2Ecn6TRO3lHGoOPmp53UH4n4oh5-q-HO2e3UkWdQ0kEpTmjUmiWksC99cQcxZTKRIahfzoFVYw8-xQ6SuAW8v_rKQnLiXt3DlnPT6EGyXlTM_T_M1Oi0h57dT0jz4dLZhq0SNrF0s8w6s6HQX1os-ku97INuMqOFT_VrQ0VlRkMLGhj13-5xFacJG2YwRlZCNUqZoqaf7MOjcvlx37bIfgq0QJmW28LlqtgyXWio_dgxGZo9YSsYYHQRKK1dHIvB10oyUdiJPJgK3F0nO46VrhHsAtXSc6kNg2o0TESMUMZiVykAGwtMtjNzN2AQiSgILnMoOoSrFwqlnxVu4lDkm24VouzC3XehYcLl4ZlJIZfw5ul6ZNyy3zSzkPqZXBCl8C84Xt9Hh6RQjSvV4TmMcTLsQlwoLrqplWU7x-xuP_jf8DDb6N53w8a73cAybnJwk5_DVoZZN5_oEsUgWn-bu9gG-V8-r
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+comprehensive+review+of+SHP2+and+its+role+in+cancer&rft.jtitle=Cellular+oncology+%28Dordrecht%29&rft.au=Asmamaw+Moges+Dessale&rft.au=Xiao-Jing%2C+Shi&rft.au=Li-Rong%2C+Zhang&rft.au=Hong-Min%2C+Liu&rft.date=2022-10-01&rft.pub=Springer+Nature+B.V&rft.issn=2211-3428&rft.eissn=2211-3436&rft.volume=45&rft.issue=5&rft.spage=729&rft.epage=753&rft_id=info:doi/10.1007%2Fs13402-022-00698-1&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2211-3428&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2211-3428&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2211-3428&client=summon